Phosphodiesterase 10

ABSTRACT

The present invention provides novel human PDE10 polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, host cells transformed with the expression constructs; methods for producing PDE10 polypeptides; antisense polynucleotides; and antibodies specifically immunoreactive with the PDE10 polypeptides. The invention further provides methods to identify binding partners of PDE10, and more particularly, binding partners that modulate PDE10 enzyme activity.

[0001] This application claims priority of U.S. Provisional Application No. 60/075,508, filed Feb. 23, 1998.

FIELD OF THE INVENTION

[0002] The present invention relates generally to a novel phosphodiesterase (PDE) designated PDE10. Depending on nomenclature used, PDE10 is also referred to as PDE9.

BACKGROUND OF THE INVENTION

[0003] Phosphodiesterases (PDEs) hydrolyze 3′, 5′ cyclic nucleotides to their respective nucleoside 5′ monophosphates. The cyclic nucleotides cAMP and cGMP are synthesized by adenylyl and guanylyl cyclases, respectively, and serve as second messengers in a number of cellular signaling pathways. The duration and strength of the second messenger signal is a function of the rate of synthesis and the rate of hydrolysis of the cyclic nucleotide.

[0004] Multiple families of PDEs have been identified. The nomenclature system includes first a number that indicates the PDE family. To date, nine families (PDE1-9) are known which are classified by: (i) primary structure; (ii) substrate preference; (iii) response to different modulators; (iv) sensitivity to specific inhibitors; and (v) modes of regulation [Loughney and Ferguson, in Phosphodiesterase Inhibitors, Schudt, et al. (Eds.), Academic Press: New York, N.Y. (1996) pp.1-19]. The number indicating the family is followed by a capital letter, indicating a distinct gene, and the capital letter followed by a second number, indicating a specific splice variant or a specific transcript that utilizes a unique transcription initiation site.

[0005] The amino acid sequences of all mammalian PDEs identified to date include a highly conserved region of approximately 270 amino acids located in the carboxy terminal half of the protein [Charbonneau, et al., Proc. Natl. Acad. Sci. (USA) 83:9308-9312 (1986)]. The conserved domain includes the catalytic site for cAMP and/or cGMP hydrolysis and two putative zinc binding sites as well as family specific determinants [Beavo, Physiol. Rev. 75:725-748 (1995); Francis, et al., J. Biol. Chem. 269:22477-22480 (1994)]. The amino terminal regions of the various PDEs are highly variable and include other family specific determinants such as: (i) calmodulin binding sites (PDE1); (ii) non-catalytic cyclic GMP binding sites (PDE2, PDE5, PDE6); (iii) membrane targeting sites (PDE4); (iv) hydrophobic membrane association sites (PDE3); and (v) phosphorylation sites for either the calmodulin-dependent kinase II (PDE1), the cAMP-dependent kinase (PDE1, PDE3, PDE4), or the cGMP dependent kinase (PDE5) [Beavo, Physiol. Rev. 75:725-748 (1995); Manganiello, et al., Arch. Biochem. Acta 322:1-13 (1995); Conti, et al., Physiol. Rev. 75:723-748 (1995)].

[0006] Members of the PDE1 family are activated by calcium-calmodulin. Three genes have been identified; PDE1A and PDE1B preferentially hydrolyze cGMP while PDE1C has been shown to exhibit a high affinity for both cAMP and cGMP. The PDE2 family is characterized as being specifically stimulated by cGMP [Loughney and Ferguson, supra]. Only one gene has been identified, PDE2A, the enzyme product of which is specifically inhibited by erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA). Enzymes in the PDE3 family are specifically inhibited by cGMP. Two genes are known, PDE3A and PDE3B, both having high affinity for both cAMP and cGMP, although the V_(max) for cGMP hydrolysis is low enough that cGMP functions as a competitive inhibitor for cAMP hydrolysis. PDE3 enzymes are specifically inhibited by milrinone and enoximone [Loughney and Ferguson, supra]. The PDE4 family effects cAMP hydrolysis and includes four genes, PDE4A, PDE4B, PDE4C, and PDE4D, each having multiple splice variants. Members of this family are specifically inhibited by the anti-depressant drug rolipram. Members of PDE5 family bind cGMP at non-catalytic sites and preferentially hydrolyze cGMP. Only one gene, PDE5A, has been identified. The photoreceptor PDE6 enzymes specifically hydrolyze cGMP [Loughney and Ferguson, supra]. Genes include PDE6A and PDE6B (the protein products of which dimerize and bind two copies of a smaller γ inhibitory subunit to form rod PDE), in addition to PDE6C which associates with three smaller proteins to form cone PDE. The PDE7 family effects cAMP hydrolysis but, in contrast to the PDE4 family, is not inhibited by rolipram [Loughney and Ferguson, supra]. Only one gene, PDE7A, has been identified. The PDE8 family has been shown to hydrolyze both cAMP and cGMP and is insensitive to inhibitors specific for PDEs 1-5. Depending on nomenclature used, PDE8 is also referred to as PDE10, but is distinct from PDE10 described herein. The PDE9 family preferentially hydrolyzes cAMP and is not sensitive to inhibition by rolipram, a PDE4-specific inhibitor, or isobutyl methyl xanthine (IBMX), a non-specific PDE inhibitor. Depending on nomenclature used, PDE9 is also referred to as PDE8, but is distinct from PDE8 mentioned above. To date, two genes have been identified in the PDE9 family.

[0007] Specific and non-specific inhibitors of the various PDE protein families have been shown to be effective in treating disorders attributable, in part, to aberrant levels of cAMP or cGMP. For example, the PDE4-specific inhibitor rolipram, mentioned above as an anti-depressant, inhibits lipopolysaccharide-induced expression of TNFα and has been effective in treating multiple sclerosis in an animal model. Other PDE4-specific inhibitors are being investigated for use as anti-inflammatory therapeutics, and efficacy in attenuating the late asthmatic response to allergen challenge has been demonstrated [Harbinson, et al., Eur. Respir. J. 10:1008-1014 (1997)]. Inhibitors specific for the PDE3 family have been approved for treatment of congestive heart failure. PDE5 inhibitors are currently being evaluated for treatment of penile erectile dysfunction [Boolell, et al., Int. J. Impotence Res. 8:47-50 (1996)]. Non-specific inhibitors, such as theophylline and pentoxiflline, are currently used in the treatment of respiratory and vascular disorders, respectively.

[0008] Given the importance of cAMP and cGMP in intracellular second messenger signaling, there thus exists an ongoing need in the art to identify additional PDE species. Identification of heretofore unknown families of PDEs, and genes and splice variants thereof, will provide additional pharmacological approaches to treating conditions in which cyclic nucleotide pathways are aberrant, as well as conditions in which modulation of intracellular cAMP and/or cGMP levels in certain cell types is desirable. Identification of family-specific and enzyme-specific inhibitors will permit development of therapeutic and prophylactic agents which act on desired cell types expressing PDEs and/or particular metabolic pathways regulated by cyclic nucleotide monophosphate steady-state concentrations.

SUMMARY OF THE INVENTION

[0009] In brief, the prevent invention provides purified and isolated PDE10 polypeptides. Preferred polypeptides comprise the amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 18, SEQ ID NO: 20 and SEQ ID NO: 22.

[0010] The invention also provides polynucleotides encoding polypeptides of the invention. A preferred polynucleotide comprises the sequence set forth in SEQ ID NO: 1. Polynucleotides of the invention include polynucleotides encoding a human PDE10 polypeptide selected from the group consisting of: a) the polynucleotide according to SEQ ID NO: 1, 18, 20 or 22; b) a DNA which hybridizes under moderately stringent conditions to the non-coding strand of the polynucleotide of (a); and c) a DNA which would hybridize to the non-coding strand of the polynucleotide of (a) but for the redundancy of the genetic code. Polynucleotides of the invention comprise any one of the polynucleotide set out in SEQ ID NO: 18, SEQ ID NO: 20, and SEQ ID NO: 22, as well as fragments thereof. The invention provide polynucleotides which are DNA molecules. DNA molecules include cDNA, genomic DNA, and wholly or partially chemically synthesized DNA molecule. The invention also provides antisense polynucleotides which specifically hybridizes with the complement of a polynucleotide of the invention.

[0011] The invention also provides expression constructs comprising a polynucleotide of the invention, host cells transformed or transfected with an expression construct of the invention, and methods for producing a PDE10 polypeptide comprising the steps of: a) growing the host cell of the invention under conditions appropriate for expression of the PDE10 polypeptide and b) isolating the PDE10 polypeptide from the host cell or the medium of its growth.

[0012] The invention further provides antibodies specifically immunoreactive with a polypeptide of the invention. Preferably, the antibody is a monoclonal antibody. The invention also provides hybridomas which produces an antibody of the invention. Anti-idiotype antibody specifically immunoreactive with the antibody of the invention are also contemplated.

[0013] The invention also provides methods to identify a specific binding partner compound of a PDE10 polypeptide comprising the steps of: a) contacting the PDE10 polypeptide with a compound under conditions which permit binding between the compound and the PDE10 polypeptide; b) detecting binding of the compound to the PDE10 polypeptide; and c) identifying the compound as a specific binding partner of the PDE10 polypeptide. Preferably, methods of the invention identify specific binding partners that modulate activity of the PDE10 polypeptide. In one aspect, the methods identify compounds that inhibits activity of the PDE10 polypeptide. In another aspect, the methods identify compounds that enhance activity of the PDE10 polypeptide.

[0014] The invention also provides methods to identify a specific binding partner compound of the PDE10 polynucleotide of the invention comprising the steps of: a) contacting the PDE10 polynucleotide with a compound under conditions which permit binding between the compound and the PDE10 polynucleotide; b) detecting binding of the compound to the PDE10 polynucleotide; and c) identifying the compound as a specific binding partner of the PDE10 polynucleotide. Preferably, the methods identify specific binding partner compounds that modulate expression of a PDE10 polypeptide encoded by the PDE10 polynucleotide. In one aspect, method of the invention identify compounds that inhibit expression of the PDE10 polypeptide. In another aspect, methods of the invention identify compounds that enhance expression of the PDE10 polypeptide.

[0015] Binding partner compounds identified by methods of the invention are also contemplated, as are compositions comprising the compound. The invention further comprehends use of binding partner compounds of the invention in production of medicaments for the treatment of PDE10-related disorders.

DETAILED DESCRIPTION OF THE INVENTION

[0016] The present invention provides polypeptides and underlying polynucleotides for a novel PDE family designated PDE10. The PDE10 family is distinguished from previously known PDE families in that it shows a lower degree of sequence homology than would be expected for a member of a known family of PDEs and it is not sensitive to inhibitors that are known to be specific for previously identified PDE families. Outside of the catalytic region of the protein, PDE10 shows little homology to other known PDEs. Even over the catalytic region, PDE10 amino acid sequence identity is less than 40% when compared with the same region in known PDEs. The invention includes both naturally occurring and non-naturally occurring PDE10 polynucleotides and polypeptide products thereof. Naturally occurring PDE10 products include distinct gene and polypeptide species within the PDE10 family; these species include those which are expressed within cells of the same animal as well as corresponding species homologs expressed in cells of other animals. Within each PDE10 species, the invention further provides splice variants encoded by the same polynucleotide but which arise from distinct mRNA transcripts. Non-naturally occurring PDE10 products include variants of the naturally occurring products such as analogs (i.e., wherein one or more amino acids are added, substituted, or deleted) and those PDE10 products which include covalent modifications (i.e., fusion proteins, glycosylation variants, and the like).

[0017] The present invention provides novel purified and isolated polynucleotides (e.g., DNA sequences and RNA transcripts, both sense and complementary antisense strands, including splice variants thereof) encoding human PDE10s. DNA sequences of the invention include genomic and cDNA sequences as well as wholly or partially chemically synthesized DNA sequences. Genomic DNA of the invention comprises the protein coding region for a polypeptide of the invention and includes allelic variants of the preferred polynucleotide of the invention. Genomic DNA of the invention is distinguishable from genomic DNAs encoding polypeptides other than PDE10 in that it includes the PDE10 coding region as defined by PDE10 cDNA of the invention. The invention therefore provides structural, physical, and functional characterization for genomic PDE10 DNA. Allelic variants are known in the art to be modified forms of a wild type gene sequence, the modification resulting from recombination during chromosomal segregation or exposure to conditions which give rise to genetic mutation. Allelic variants, like wild type genes, are inherently naturally occurring sequences (as opposed to non-naturally occurring variants which arise from in vitro manipulation). “Synthesized,” as used herein and is understood in the art, refers to purely chemical, as opposed to enzymatic, methods for producing polynucleotides. “Wholly” synthesized DNA sequences are therefore produced entirely by chemical means, and “partially” synthesized DNAs embrace those wherein only portions of the resulting DNA were produced by chemical means. A preferred DNA sequence encoding a human PDE10 polypeptide is set out in SEQ ID NO: 1. The worker of skill in the art will readily appreciate that the preferred DNA of the invention comprises a double stranded molecule, for example the molecule having the sequence set forth in SEQ ID NO: 1 along with the complementary molecule (the “non-coding strand” or “complement”) having a sequence deducible from the sequence of SEQ ID NO: 1 according to Watson-Crick base paring rules for DNA. Also preferred are polynucleotides encoding the PDE10 polypeptide of SEQ ID NO: 2.

[0018] The disclosure of a full length polynucleotide encoding a PDE10 polypeptide makes readily available to the worker of ordinary skill in the art every possible fragment of the full length polynucleotide. The invention therefore provides fragments of PDE10-encoding polynucleotides of the invention comprising at least 10 to 20, and preferably at least 15, nucleotides, however, the invention comprehends fragments of various lengths. Preferably, fragment polynucleotides of the invention comprise sequences unique to the PDE10-encoding polynucleotide sequence, and therefore hybridize under stringent or preferably moderate conditions only (i.e., “specifically”) to polynucleotides encoding PDE10, or PDE10 polynucleotide fragments containing the unique sequence. Polynucleotide fragments of genomic sequences of the invention comprise not only sequences unique to the coding region, but also include fragments of the full length sequence derived from introns, regulatory regions, and/or other non-translated sequences. Sequences unique to polynucleotides of the invention are recognizable through sequence comparison to other known polynucleotides, and can be identified through use of alignment programs made available in public sequence databases.

[0019] The invention also provides fragment polynucleotides that are conserved in one or more polynucleotides encoding members of the PDE10 family of polypeptides. Such fragments include sequences characteristic of the family of PDE10 polynucleotides, and are also referred to as “signature sequences.” The conserved signature sequences are readily discernable following simple sequence comparison of polynucleotides encoding members of the PDE10 family. Fragments of the invention can be labeled in a manner that permits their detection, and radioactive and non-radioactive labeling are comprehended. Fragment polynucleotides are particularly useful as probes for detection of full length or other fragment PDE10 polynucleotides. One or more fragment polynucleotides can be included in kits that are used to detect the presence of a polynucleotide encoding PDE10, or used to detect variations in a polynucleotide sequence encoding PDE10.

[0020] The invention further embraces species homologs, preferably mammalian, of the human PDE10 DNA. The polynucleotide sequence information provided by the invention makes possible the identification and isolation of polynucleotides encoding related mammalian PDE10 molecules by well known techniques including Southern and/or Northern hybridization, and polymerase chain reaction (PCR). Examples of related polynucleotides include human and non-human genomic sequences, including allelic variants, as well as polynucleotides encoding polypeptides homologous to PDE10 and structurally related polypeptides sharing one or more biological, immunological, and/or physical properties of PDE10.

[0021] The invention also embraces DNA sequences encoding PDE10 species which hybridize under moderately stringent conditions to the non-coding strands, or complements, of the polynucleotide in any one of SEQ ID NOs: 1, 18, 20, and 22. DNA sequences encoding PDE10 polypeptides which would hybridize thereto but for the redundancy of the genetic code are contemplated by the invention. Exemplary moderate hybridization conditions are as follows: hybridization at 65° C. in 3×SSC, 0.1% Sarkosyl, and 20 mM sodium phosphate, pH 6.8, and washing at 65° C. in 2×SSC with 0.1% SDS. Exemplary high stringency conditions would include a final wash in 0.2×SSC/0.1% SDS, at 65° C. to 75° C. It is understood in the art that conditions of equivalent stringency can be achieved through variation of temperature and buffer, or salt concentration as described Ausebel, et al. (Eds.), Protocols in Molecular Biology, John Wiley & Sons (1994), pp.6.0.3 to 6.4.10. Modifications in hybridization conditions can be empirically determined or precisely calculated based on the length and the percentage of guanosine/cytosine (GC) base pairing of the probe. The hybridization conditions can be calculated as described in Sambrook, et al., (Eds.), Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, N.Y. (1989), pp. 9.47 to 9.51.

[0022] Autonomously replicating recombinant expression constructions such as plasmid and viral DNA vectors incorporating PDE10 sequences are also provided. Expression constructs wherein PDE10-encoding polynucleotides are operatively-linked to an endogenous or exogenous expression control DNA sequence and a transcription terminator are also provided.

[0023] According to another aspect of the invention, host cells are provided, including procaryotic and eucaryotic cells, either stably or transiently transformed with DNA sequences of the invention in a manner which permits expression of PDE10 polypeptides of the invention. Expression systems of the invention include bacterial, yeast, fungal, viral, invertebrate, and mammalian cells systems. Host cells of the invention are a valuable source of immunogen for development of antibodies specifically immunoreactive with PDE10. Host cells of the invention are also conspicuously useful in methods for large scale production of PDE10 polypeptides wherein the cells are grown in a suitable culture medium and the desired polypeptide products are isolated from the cells or from the medium in which the cells are grown by, for example, immunoaffinity purification.

[0024] Knowledge of PDE10 DNA sequences allows for modification of cells to permit, or increase, expression of endogenous PDE10. Cells can be modified (e.g., by homologous recombination) to provide increased PDE10 expression by replacing, in whole or in part, the naturally occurring PDE10 promoter with all or part of a heterologous promoter so that the cells express PDE10 at higher levels. The heterologous promoter is inserted in such a manner that it is operatively-linked to PDE10 encoding sequences. See, for example, PCT International Publication No. WO 94/12650, PCT International Publication No. WO 92/20808, and PCT International Publication No. WO 91/09955. The invention also comprehends that, in addition to heterologous promoter DNA, amplifiable marker DNA (e.g., ada, dhfr, and the multifunctional CAD gene which encodes carbamyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along with the heterologous promoter DNA. If linked to the PDE10 coding sequence, amplification of the marker DNA by standard selection methods results in co-amplification of the PDE10 coding sequences in the cells.

[0025] The DNA sequence information provided by the present invention also makes possible the development through, e.g. homologous recombination or “knock-out” strategies [Capecchi, Science 244:1288-1292 (1989)], of animals that fail to express functional PDE10 or that express a variant of PDE10. Such animals are useful as models for studying the in vivo activities of PDE10 and modulators of PDE10.

[0026] The invention also provides purified and isolated mammalian PDE10 polypeptides as set out in SEQ ID NOs: 2, 19, 21, and 23. Presently preferred is a PDE10 polypeptide comprising the amino acid sequence set out in SEQ ID NO: 2. The invention embraces PDE10 polypeptides encoded by a DNA selected from the group consisting of: a) the DNA sequence set out in SEQ ID NOs:1, 18, 20, or 22; b) a DNA molecule which hybridizes under stringent conditions to the noncoding strand of the protein coding portion of (a); and c) a DNA molecule that would hybridize to the DNA of (a) but for the degeneracy of the genetic code. The invention also embraces polypeptide fragments of the sequences set out in SEQ ID NOs: 2, 19, 21, or 23 wherein the fragments maintain biological or immunological properties of a PDE10 polypeptide. Preferred polypeptide fragments display antigenic properties unique to or specific for the PDE10 family of polypeptides. Fragments of the invention can be prepared by any the methods well known and routinely practiced in the art, having the desired biological and immunological properties.

[0027] The invention embraces polypeptides have at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55% and at least 50% identity and/or homology to the preferred PDE10 polypeptide on the invention. Percent amino acid sequence “identity” with respect to the preferred polypeptide of the invention is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the residues in the PDE10 sequence after aligning both sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Percent sequence “homology” with respect to the preferred polypeptide of the invention is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the residues in the PDE10 sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and also considering any conservative substitutions as part of the sequence identity. Conservative substitutions can be defined as set out below.

[0028] PDE10 polypeptides of the invention may be isolated from natural cell sources or may be chemically synthesized, but are preferably produced by recombinant procedures involving host cells of the invention. Use of various host cells is expected to provide for such post-translational modifications (e.g., glycosylation, truncation, lipidation, and phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the invention. PDE10 products of the invention may be full length polypeptides, biologically or immunologically active fragments, or variants thereof which retain specific PDE10 biological or immunological activity. Variants may comprise PDE10 polypeptide analogs wherein one or more of the specified (i.e., naturally encoded) amino acids is deleted or replaced or wherein one or more non-specified amino acids are added: (1) without loss of one or more of the biological activities or immunological characteristics specific for PDE10; or (2) with specific disablement of a particular biological activity of PDE10.

[0029] Variant products of the invention include mature PDE10 products, i.e., PDE10 products wherein leader or signal sequences are removed, and having additional, non-naturally occurring, amino terminal residues. PDE10 products having an additional methionine residue at position −1 (Met⁻¹-PDE10) are contemplated, as are PDE10 products having additional methionine and lysine residues at positions −2 and −1 (Met⁻²-Lys⁻¹-PDE10). Variants of these types are particularly useful for recombinant protein production in bacterial cell types.

[0030] The invention also embraces PDE10 variants having additional amino acid residues that result from use of specific expression systems. For example, use of commercially available vectors that express a desired polypeptide such as a glutathione-S-transferase (GST) fusion product provide the desired polypeptide having an additional glycine residue at position −1 as a result of cleavage of the GST component from the desired polypeptide. Variants which result from expression in other vector systems are also contemplated.

[0031] Variant polypeptides include those wherein conservative substitutions have been introduced by modification of polynucleotides encoding polypeptides of the invention. Conservative substitutions are recognized in the art to classify amino acids according to their related physical properties and can be defined as set out in Table I (from WO 97/09433, page 10, published Mar. 13, 1997 (PCT/GB96/02197, filed Sep. 6, 1996). TABLE I Conservative Substitutions I SIDE CHAIN CHARACTERISTIC AMINO ACID Aliphatic Non-polar G A P I L V Polar-uncharged C S T M N Q Polar-charged D E K R Aromatic H F W Y Other N Q D E

[0032] Alternatively, conservative amino acids can be grouped as defined in Lehninger, [Biochemistry, Second Edition; Worth Publishers, Inc. NY:N.Y. (1975), pp.71-77] as set out in Table II. TABLE II Conservative Substitutions II SIDE CHAIN CHARACTERISTIC AMINO ACID Non-polar (hydrophobic) A. Aliphatic: A L I V P B. Aromatic: F W C. Sulfur-containing: M D. Borderline: G Uncharged-polar A. Hydroxyl: S T Y B. Amides: N Q C. Sulfhydryl: C D. Borderline: G Positively Charged (Basic): K R H Negatively Charged (Acidic): D E

[0033] The invention further embraces PDE10 products modified to include one or more water soluble polymer attachments. Particularly preferred are PDE10 products covalently modified with polyethylene glycol (PEG) subunits. Water soluble polymers may be bonded at specific positions, for example at the amino terminus of the PDE10 products, or randomly attached to one or more side chains of the polypeptide.

[0034] Also comprehended by the present invention are antibodies (e.g., monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, human antibodies CDR-grafted antibodies, or otherwise “humanized” antibodies, antigen binding antibody domains including Fab, Fab′, F(ab′)₂, F_(v), or single variable domains, and the like) and other binding proteins specific for PDE10 products or fragments thereof. Specific binding proteins can be developed using isolated or recombinant PDE10 products, PDE10 variants, or cells expressing such products. The term “specific for” indicates that the variable regions of the antibodies recognize and bind PDE10 polypeptides exclusively (i.e., able to distinguish PDE10 polypeptides from the superfamily of PDE polypeptides despite sequence identity, homology, or similarity found in the family of polypeptides), but may also interact with other proteins (for example, S. aureus protein A or other antibodies in ELISA techniques) through interactions with sequences outside the variable region of the antibodies, and in particular, in the constant region of the molecule. Screening assays to determine binding specificity of an antibody of the invention are well known and routinely practiced in the art. For a comprehensive discussion of such assays, see Harlow et al. (eds), Antibodies: A Laboratory Manual; Cold Spring Harbor Laboratory; Cold Spring Harbor, N.Y. (1988), Chapter 6. Antibodies that recognize and bind fragments of the PDE10 polypeptides of the invention are also contemplated, provided that the antibodies are first and foremost specific for, as defined above, PDE10 polypeptides. As with antibodies that are specific for full length PDE10 polypeptides, antibodies of the invention that recognize PDE10 fragments are those which can distinguish PDE10 polypeptides from the superfamily of PDE polypeptides despite inherent sequence identity, homology, or similarity found in the family of proteins.

[0035] Binding proteins are useful for purifying PDE10 products and detection or quantification of PDE10 products in fluid and tissue samples using known immunological procedures. Binding proteins are also manifestly useful in modulating (i.e., blocking, inhibiting or stimulating) biological activities of PDE10, especially those activities involved in signal transduction. Anti-idiotypic antibodies specific for anti-PDE10 antibodies are also contemplated.

[0036] The scientific value of the information contributed through the disclosures of DNA and amino acid sequences of the present invention is manifest. As one series of examples, knowledge of the sequence of a cDNA for PDE10 makes possible through use of Southern hybridization or polymerase chain reaction (PCR) the identification of genomic DNA sequences encoding PDE10 and PDE10 expression control regulatory sequences such as promoters, operators, enhancers, repressors, and the like. DNA/DNA hybridization procedures carried out with DNA sequences of the invention under moderately to highly stringent conditions are likewise expected to allow the isolation of DNAs encoding allelic variants of PDE10; allelic variants are known in the art to include structurally related proteins sharing one or more of the biochemical and/or immunological properties specific to PDE10. Similarly, non-human species genes encoding proteins homologous to PDE10 can also be identified by Southern and/or PCR analysis and useful in animal models for PDE10-related disorders. As an alternative, complementation studies can be useful for identifying other human PDE10 products as well as non-human proteins, and DNAs encoding the proteins, sharing one or more biological properties of PDE10. Polynucleotides of the invention are also useful in hybridization assays to detect the capacity of cells to express PDE10. Polynucleotides of the invention may also be the basis for diagnostic methods useful for identifying a genetic alteration(s) in a PDE10 locus that underlies a disease state or states.

[0037] The DNA and amino acid sequence information provided by the present invention also makes possible the systematic analysis of the structure and function of PDE10s. DNA and amino acid sequence information for PDE10 also permits identification of binding partner compounds with which a PDE10 polypeptide or polynucleotide will interact. Binding partner compounds include proteins and non-protein compounds such as small molecules. Agents that modulate (i.e., increase, decrease, or block) PDE10 activity or expression may be identified by incubating a putative modulator with a PDE10 polypeptide or polynucleotide and determining the effect of the putative modulator on PDE10 phosphodiesterase activity or expression. The selectivity of a compound that modulates the activity of the PDE10 can be evaluated by comparing its binding activity on the PDE10 to its activity on other PDE enzymes. Cell based methods, such as di-hybrid assays to identify DNAs encoding binding compounds and split hybrid assays to identify inhibitors of PDE10 polypeptide interaction with a known binding polypeptide, as well as in vitro methods, including assays wherein a PDE10 polypeptide, PDE10 polynucleotide, or a binding partner are immobilized, and solution assays are contemplated under the invention.

[0038] Selective modulators may include, for example, antibodies and other proteins or peptides which specifically bind to a PDE10 polypeptide or a PDE10-encoding nucleic acid, oligonucleotides which specifically bind to a PDE10 polypeptide or a PDE10 gene sequence, and other non-peptide compounds (e.g., isolated or synthetic organic and inorganic molecules) which specifically react with a PDE10 polypeptide or underlying nucleic acid. Mutant PDE10 polypeptides which affect the enzymatic activity or cellular localization of the wild-type PDE10 polypeptides are also contemplated by the invention. Presently preferred targets for the development of selective modulators include, for example: (1) regions of the PDE10 polypeptide which contact other proteins and/or localize the PDE10 polypeptide within a cell, (2) regions of the PDE10 polypeptide which bind substrate, (3) cyclic nucleotide-binding site(s) of the PDE10 polypeptide, (4) phosphorylation site(s) of the PDE10 polypeptide and (5) regions of the PDE10 polypeptide which are involved in multimerization of PDE10 subunits. Still other selective modulators include those that recognize specific PDE10 encoding and regulatory polynucleotide sequences. Modulators of PDE10 activity may be therapeutically useful in treatment of a wide range of diseases and physiological conditions in which PDE activity is known to be involved.

[0039] PDE10 polypeptides of the invention are particularly amenable to use in high throughput screening assays to identify binding partners, and preferably modulators. Cell based assays are contemplated, including yeast based assay systems as well as mammalian cell expression systems as described in Jayawickreme and Kost, Curr. Opin. Biotechnol. 8:629-634 (1997). Alternatively, automated and minaturized high throughput screening (HTS)assays, such as high density free format high density screening, as described in Houston and Banks, Curr. Opin. Biotehcnol. 8:734-740 (1997). Combinatorial libraries are particularly useful in high throughput screening assays.

[0040] There are a number of different libraries used for the identification of small molecule modulators, including, (1) chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of random peptides, oligonucleotides or organic molecules.

[0041] Chemical libraries consist of structural analogs of known compounds or compounds that are identified as “hits” or “leads” via natural product screening. Natural product libraries are collections of microorganisms, animals, plants, or marine organisms which are used to create mixtures for screening by: (1) fermentation and extraction of broths from soil, plant or marine microorganisms or (2) extraction of plants or marine organisms. Natural product libraries include polyketides, non-ribosomal peptides, and variants (non-naturally occurring) variants thereof. For a review, see Science 282:63-68 (1998). Combinatorial libraries are composed of large numbers of peptides, oligonucleotides, or organic compounds as a mixture. They are relatively easy to prepare by traditional automated synthesis methods, PCR, cloning or proprietary synthetic methods. Of particular interest are peptide and oligonucleotide combinatorial libraries. Still other libraries of interest include protein, peptidomimetic, multiparallel synthetic collection, recombinatorial, and polypeptide libraries. For a review of combinatorial chemistry and libraries created therefrom, see Myers, Curr. Opion. Biotechnol. 8:701-707 (1997). Identification of modulators through use of the various libraries described herein permits modification of the candidate “hit” (or “lead”) to optimize the capacity of the “hit” to modulate activity.

[0042] Also made available by the invention are anti-sense polynucleotides which recognize and hybridize to polynucleotides encoding PDE10. Full length and fragment anti-sense polynucleotides are provided. The worker of ordinary skill will appreciate that fragment anti-sense molecules of the invention include (i) those which specifically recognize and hybridize to PDE10 RNA (as determined by sequence comparison of DNA encoding PDE10 to DNA encoding other known molecules) as well as (ii) those which recognize and hybridize to RNA encoding variants in the PDE10 family of proteins. Antisense polynucleotides that hybridize to RNA encoding other members of the PDE10 family of proteins are also identifiable through sequence comparison to identify characteristic, or signature, sequences for the family of molecules. Anti-sense polynucleotides are particularly relevant to regulating expression of PDE10 by those cells expressing PDE10 mRNA.

[0043] Antisense nucleic acids (preferably 10 to 20 base pair oligonucleotides) capable of specifically binding to PDE10 expression control sequences or PDE10 RNA are introduced into cells (e.g., by a viral vector or colloidal dispersion system such as a liposome). The antisense nucleic acid binds to the PDE10 target nucleotide sequence in the cell and prevents transcription or translation of the target sequence. Phosphorothioate and methylphosphonate antisense oligonucleotides are specifically contemplated for therapeutic use according to the invention. The antisense oligonucleotides maybe further modified by poly-L-lysine, transferrin polylysine, or cholesterol moieties at the 540 end.

[0044] The invention further comprehends methods to modulate PDE10 expression through use of ribozymes. For a review, see Gibson and Shillitoe, Mol. Biotech. 7:125-137 (1997). Ribozyme technology can be utilized to inhibit translation of PDE10 mRNA in a sequence specific manner through (i) the hybridization of a complementary RNA to a target mRNA and (ii) cleavage of the hybridized mRNA through nuclease activity inherent to the complementary strand. Ribozymes can identified by empirical methods but more preferably are specifically designed based on accessible sites on the target mRNA [Bramlage, et al., Trends in Biotech 16:434-438 (1998).] Delivery of ribozymes to target cells can be accomplished using either exogenous or endogenous delivery techniques well known and routinely practiced in the art. Exogenous delivery methods can include use of targeting liposomes or direct local injection. Endogenous methods include use of viral vectors and non-viral plasmids.

[0045] Ribozymes can specifically modulate expression of PDE10 when designed to be complementary to regions unique to a polynucleotide encoding PDE10. “Specifically modulate” therefore is intended to mean that ribozymes of the invention recognizes only a polynucleotide encoding PDE10. Similarly, ribozymes can be designed to modulate expression of all or some of the PDE10 family of proteins. Ribozymes of this type are designed to recognize polynucleotide sequences conserved in all or some of the polynucleotides which encode the family of proteins.

[0046] The invention further embraces methods to modulate transcription of PDE10 through use of oligonucleotide-directed triplet helix formation. For a review, see Lavrosky, et al., Biochem. Mol. Med. 62:11-22 (1997). Triplet helix formation is accomplished using sequence specific oligonucleotides which hybridize to double stranded DNA in the major groove as defined in the Watson-Crick model. Hybridization of a sequence specific oligonucleotide can thereafter modulate activity of DNA-binding proteins, including, for example, transcription factors and polymerases. Preferred target sequences for hybridization include promoter and enhancer regions to permit transcriptional regulation of PDE10 expression. Oligonucleotides which are capable of triplet helix formation are also useful for site-specific covalent modification of target DNA sequences. Oligonucleotides useful for covalent modification are coupled to various DNA damaging agents as described in Lavrovsky, et al. [supra].

[0047] The invention comprehends mutations in the PDE10 gene that result in loss of normal function of the PDE10 gene product and underlie human disease states in which failure of the PDE10 is involved. Gene therapy to restore PDE10 activity would thus be indicated in treating those disease states. Delivery of a functional PDE10 gene to appropriate cells is effected ex vivo, in situ, or in vivo by use of vectors, and more particularly viral vectors (e.g., adenovirus, adeno-associated virus, or a retrovirus), or ex vivo by use of physical DNA transfer methods (e.g., liposomes or chemical treatments). See, for example, Anderson, Nature, supplement to vol. 392, no. 6679, pp.25-20 (1998). For additional reviews of gene therapy technology see Friedmann, Science, 244: 1275-1281 (1989); Verma, Scientfic American: 68-84(1990); and Miller, Nature, 357:455-460 (1992). Alternatively, it is contemplated that in other human disease states, preventing the expression of or inhibiting the activity of PDE10 will be useful in treating the disease states. It is contemplated that antisense therapy or gene therapy could be applied to negatively regulate the expression of PDE10.

[0048] Identification of modulators of PDE10 expression and/or biological activity provides methods to treat disease states that arise from aberrant PDE10 activity. Modulators may be prepared in compositions for administration, and preferably include one or more pharmaceutically acceptable carriers, such as pharmaceutically acceptable (i.e., sterile and non-toxic) liquid, semisolid, or solid diluents that serve as pharmaceutical vehicles, excipients, or media. Any diluent known in the art may be used. Exemplary diluents include, but are not limited to, polyoxyethylene sorbitan monolaurate, magnesium stearate, methyl- and propylhydroxybenzoate, talc, alginates, starches, lactose, sucrose, dextrose, sorbitol, mannitol, gum acacia, calcium phosphate, mineral oil, cocoa butter, and oil of theobroma. The modulator compositions can be packaged in forms convenient for delivery. The compositions can be enclosed within a capsule, sachet, cachet, gelatin, paper, or other container. These delivery forms are preferred when compatible with entry of the composition into the recipient organism and, particularly, when the composition is being delivered in unit dose form. The dosage units can be packaged, e.g., in tablets, capsules, suppositories or cachets. The compositions may be introduced into the subject by any conventional method including, e.g., by intravenous, intradermal, intramuscular, intramammary, intraperitoneal, or subcutaneous injection; by oral, sublingual, nasal, anal, vaginal, or transdermal delivery; or by surgical implantation, e.g., embedded under the splenic capsule or in the cornea. The treatment may consist of a single dose or a plurality of doses over a period of time.

[0049] The invention also embraces use of a PDE10 polypeptide, a PDE10 polynucleotide, or a binding partner thereof in production of a medicament for treatment of a PDE10-related biological disorder.

[0050] The present invention is illustrated by the following examples relating to the isolation of a polynucleotide encoding a PDE10 polypeptide and expression thereof. Example 1 describes identification of an EST encoding a partial PDE10 polypeptide and isolation of a full length PDE10-encoding clone. Example 2 relates to Northern blot analysis of PDE10 expression. Example 3 addresses chromosome mapping of PDE10. Example 4 describes expression and characterization of a recombinant PDE10 polypeptide. Example 5 describes production of anti-PDE10 antibodies. Example 6 provides an analysis of PDE10 expression using in situ hybridization. Example 7 relates to high throughput screening to identify inhibitors of PDE10.

EXAMPLE 1 Identification of an EST Related to a Human PDE and Isolation of a Full Length PDE10-encoding Polynucleotide

[0051] Using the sequences of known human, 3′, 5′ cyclic nucleotide phosphodiesterases, a search of the National Center for Biotechnology Information (NCBI) Expressed Sequence Tags (EST) database was undertaken in order to identify cDNA fragments that could potentially be useful for the identification of novel phosphodiesterase (PDE) genes. This database contains DNA sequences representing one or both ends of cDNAs collected from a variety of tissue sources. A single sequencing run is performed on one or both ends of the cDNA and the quality of the DNA sequence varies tremendously. At the time the PDE searches were performed, the EST sequence database contained more than 600,000 cDNA sequences from a variety of organisms.

[0052] The search for novel PDE sequences included three steps. First, the BLASTN program available through NCBI was used to identify DNA sequences in the EST sequence database with homology to cDNA sequences encoding known human PDEs. The program compares a nucleotide query sequence against a nucleotide sequence database. The cDNA sequences of the fifteen known human PDEs were submitted and fifteen BLASTN searches were performed; the query PDE sequences included PDE1A3 [Loughney, et al., J. Biol. Chem. 271:796-806 (1996)], PDE1B1 [Yu, et al., Cell Signaling, 9:519-529 (1997)], PDE1C2 [Loughney, et al., J. Biol. Chem. 271:796-806 (1996)], PDE2A3 [Rosman, et al., Gene 191:89-95 (1997)], PDE3A [Meacci, et al., Proc. Natl. Acad. Sci. (USA) 89:3721-3725 (1992)], PDE3B [Miki et al., Genomics 36:476-485 (1996)], PDE4A5 [Bolger,et al., Mol. Cell. Biol. 13:6558-6571 (1993)], PDE4B2 [Bolger, et al., Mol. Cell. Biol. 13:6558-6571 (1993)], PDE4C [Bolger, et al., Mol. Cell Biol. 13:6558-6571 (1993)], PDE4D1 [Bolger, et al., Biochem. J. 328:539-548 (1997)] and PDE4D3 [Bolger, et al., Mol. Cell. Biol. 13:6558-6571 (1993)], PDE5A, PDE6A [Pittler, et al., Genomics 6:272-283 (1990)], PDE6B [Collins, et al., Genomics 13:698-704 (1992)], PDE6C [Piriev, et al., Genomics 28:429-435 (1995), and PDE7A1 [Michaeli, et al., J. Biol Chem. 17:12925-12932 (1993)]. The BLASTN results were examined and EST sequences that were judged as corresponding to each of the fifteen known PDE cDNAs were identified and collected into a table. The PDE6A and PDE6B sequences used as queries were truncated at 3′ end (removing a portion of the 3′ untranslated region) due to the presence of repetitive elements in the 3′ untranslated region of the cDNAs.

[0053] Secondly, the NCBI TBLASTN program was used to examine the homology between the protein sequence of the fifteen known human PDEs (as above) and the six different possible proteins encoded by each of the EST DNA sequences. In this search, the EST sequences are translated in the six possible reading frames and the amino acid sequences generated are compared to the query PDE amino acid sequences. Sequences identified as homologous at the amino acid level were examined and any EST sequences positively identified as corresponding to a known PDE during the BLASTN search described above were discarded.

[0054] The third step of the search involved analyzing the sequences that were not known PDEs. These amino acid sequences were homologous to a known PDE but were not identified as one of the 15 known PDE genes during the BLASTN searches.

[0055] The initial BLAST searches identified three EST sequences, designated X88347 (SEQ ID NO: 3), X88467 (SEQ ID NO: 4), and X88465 (SEQ ID NO: 5), that were obtained from an exon trapping experiment using chromosome 21 genomic DNA and found to encode an amino acid sequence having homology to the catalytic region of one or more of the PDE query sequences. X88347 showed homology with the amino acid sequences of PDE1A, 1B, 1C, 3A, 3B, 4A, 4B and 4D; X88467 showed homology to PDE1A, 1B, 1C, 4A, 4B, 4C, and D4; and X88465 was homologous to PDE1A and 1B amino acid sequences. At the 5′ terminus, EST X88465 was 58 nucleotides shorter than was X88467 and was not considered further.

[0056] When X88347 was translated from nucleotides 1-222 and the resultant protein was compared to PDE1A, the two proteins were the same at 23 of 51 amino acid positions (45% identity). When X88467 was translated from nucleotide 3 to 155 and the resultant protein compared to PDE1A, 15 of 36 amino acids were the same (42% identity). Because ESTs X88347 and X88467 showed homology to two different regions of the catalytic region of PDE1A, it seemed possible that they represented two different exons from a novel PDE gene.

[0057] X88347 was used as a query in a BLASTN search of the NCBI EST database. In addition to itself, X88347 identified three other human EST sequences with high enough homology to suggest the sequences were derived from the same gene. EST R00718 (SEQ ID NO: 6) showed 91% identity to X88347. R00719 (SEQ ID NO: 7) represented the 3′ -end of the same cDNA as R00718. R45187 (SEQ ID NO: 8) showed 88% identity to X88347. Two mouse cDNAs were also identified: W82786 (SEQ ID NO: 9)(91% identity) and W10517 (SEQ ID NO: 10) appeared to represent the mouse homolog of X88347. A BLASTN search using W10517 as probe identified another sequence H90802 (SEQ ID NO: 11), which appeared to represent another human EST that may be part of the human PDE gene. The several human cDNAs were not identical to each other, and the quality of the sequencing was poor. The cDNA represented by the R00719 and R00718 EST sequences was obtained from the American Type Culture Collection (Rockville, Md.) which maintains and makes publicly available deposits of ESTs identified and sequenced by I.M.A.G.E., Lawrence Livermore National Laboratory, (Livermore, Calif.). The cDNA had been isolated from a fetal liver and spleen library and mapped to chromosome 21.

[0058] R00718/9 was sequenced upon receipt and found to be consistent with the EST database sequence. The polynucleotide and amino acids sequences for R00718/9 are set out in SEQ ID Nos: 12 and 13, respectively. The R00718/9 clone contained a 0.6 kb insert with a poly A tail at the 3′-end. The open reading frame encoded a protein with homology to other PDEs but did not extend to the 5′ end of the cDNA. Beginning at amino acid position 9, a QSDRE sequence was found. Corresponding D and E residues were found within all of the query sequences. Query sequences also included a conserved E(F/Y) sequence located amino terminal to the conserved D and E residues, but this sequence was not found in EST R00718/9. Instead, the EST contained eight amino acids followed by a stop codon. The R00718/9 cDNA appeared to diverge from the PDE query sequences in the catalytic region and the open reading frame was not maintained. The disrupted open reading frame may suggest the presence of an intron that had not been removed or that the R00718/9 sequence was joined to some unidentified extraneous polynucleotide sequence. The gene represented by R00718/9 was designated PDE10.

[0059] In order to identify additional PDE10 sequences, a probe was generated based on the PDE10 sequence and used to screen cDNA libraries. First, two primers, R71S100R (SEQ ID NO: 14)and R71A521H (SEQ ID NO: 15)were synthesized for use in PCR to amplify a 420 nucleotide portion of the R00718/9 DNA fragment (nucleotides 130 to 550). Primer R71S100R generated an EcoRI restriction site in the amplification product (underlined below) and primer R71A521H generated a HindIII site (also underlined below). The PCR fragment was designed to include the region of R00718/9 homologous to other PDEs, but not the poly A tail. R7IS100R AGTCGAATTCACCGTGAGAAGTCAGAAG (SEQ ID NO: 14) R71A521H GTCAAAGCTTACATGGTCTTGTGGTGCC (SEQ ID NO: 15)

[0060] The PCR reaction contained 50 pg R00719 cDNA, 10 ng/μl each primer, 0.2 mM dNTP, 1×PCR buffer (Perkin-Elmer), 2 mM MgCl₂, and 1.25 U Taq polymerase (Perkin-Elmer). The reaction was first maintained at 94° C. for four minutes, after which thirty cycles of one minute 94° C., two minutes 50° C., and four minutes at 72° C. were performed. The PCR fragment was purified using low melting point agarose gel electrophoresis.

[0061] For library screening, the PCR fragment was labeled with ³²P with a random priming kit (Boehringer Mannheim) according to manufacturer's instructions and used to screen 10⁶ cDNAs from a human heart cDNA library (Stratagene, La Jolla, Calif.), 5×10⁵ cDNAs from a human hippocampal cDNA library (Clontech, Palo Alto, Calif.), and 7.5×10⁵ cDNAs from a human fetal brain cDNA library (Stratagene). Hybridization was carried out overnight in buffer containing 3×SSC, 0.1% Sarkosyl, 20 mM sodium phosphate, pH 6.8, 10×Denhardt's solution, and 50 μg/ml salmon sperm DNA at 65° C. Eleven positives were obtained from the fetal brain library and three from the hippocampal library. Partial sequencing led to the selection of one, FB79c, for further characterization. The polynucleotide and deduced amino acid sequences for FB79c are set out in SEQ ID NOs: 16 and 17, respectively.

[0062] FB79c contained a 1.3 kb insert; the 3′ end of FB79c extended farther than that of R00718/9 and contained 12 adenosine residues of the poly A tail of R00718/9, an EcoRI site (GGAATTC), an additional fifty-nine nucleotides and a poly A sequence. At the 5′ end, the sequence for FB79c differed from that of R00718/9 beginning at, and continuing 5′ of, nucleotide 121 of R00718/9 (corresponding to nucleotide 744 of FB79c). The open reading frame in FB79c (encoding a protein with homology to the query PDEs) did not extend to the 5′ end of the cDNA but ended in a stop codon at nucleotide 104.

[0063] A sequence within the FB79c DNA located upstream of the point of divergence from R00718/9 (but within the portion of the open reading frame with homology to the other PDEs) was the region chosen for a probe in subsequent library screening. The isolated sequence selected was a 0.36 kb EcoRV fragment extending from nucleotide 308 to nucleotide 671 of FB79c and was used to screen 1.75×10⁶ cDNAs from the fetal brain cDNA library (Stratagene). More than twenty cDNAs were identified and twelve were subjected to partial restriction mapping and DNA sequencing. More extensive sequencing on six of them led to the selection of clones FB76.2 and FB68.2 for complete sequencing. The polynucleotide and amino acid sequences for clone FB76.2 are set out in SEQ ID NOs: 18 and 19, respectively, and the polynucleotide and amino acid sequences for clone FB68.2 are set out in SEQ ID NOs. 20 and 21, respectively.

[0064] FB76.2 contained a 1.9 kb cDNA insert; the 3′ end of the cDNA stopped one nucleotide short of the poly A tail found in clone FB79c and the sequence diverged from FB79c 5′ of nucleotide 109 in clone FB79c (corresponding to nucleotide 715 in FB76.2). The open reading frame in the FB76.2 sequence that encoded a protein with homology to the PDE query sequences extended to the 5′ end of the cDNA and the first methionine was encoded beginning at nucleotide 74. Assuming this residue to be the initiating methionine, the open reading frame of FB76.2 encoded a 533 amino acid protein with a predicted molecular weight of 61,708 Da.

[0065] Clone FB68.2 contained a 2 kb cDNA insert. At the 3′ end, it extended to the poly A tail found in the FB79c sequence and the open reading frame extended to the 5′ end of the cDNA. FB68.2 differed from FB76.2 by the presence of an additional internal 180 nucleotides (nucleotides 225 to 404 of FB68.2) following corresponding nucleotide 335 of FB76.2. Since the number of additional nucleotides in the FB68.2 insertion was divisible by three, it did not alter the reading frame as compared to FB76.2. The position of the insert with respect to maintaining the same reading frame suggested that the sequence might represent an exon found in some, but not all, PDE10 cDNAs. Alternatively, the additional sequence could be an intron that had not been removed from the FB68.2 cDNA.

[0066] Because the FB76.2 and FB68.2 differed from each other, additional PDE10 DNAs were obtained and analyzed to more accurately define the PDE10 nucleotide sequence. A 5′ 0.3 kb EcoRI fragment of FB76.2 (corresponding to nucleotides 1 to 285) was isolated and used as a probe to screen 7.5×10⁵ cDNAs from the fetal brain cDNA library. Thirty seven positives were obtained, of which nineteen were first characterized with respect to fragment size (insert) that hybridized to the 0.3 kb EcoRI probe. Eight of the nineteen clones were subsequently characterized by partial sequencing. Two clones, FB93a and FB94a, contained 0.5 kb and 1.6 kb EcoRI fragments, respectively, that hybridized and were chosen for complete sequencing. The polynucleotide and amino acid sequences for clone FB93a are set out in SEQ ID NOs: 22 and 23, respectively, and the polynucleotide and amino acid sequences for clone FB94a are set out in SEQ ID NOs: 1 and 2, respectively.

[0067] FB93a contained a 1.5 kb insert which did not extend to the 3′ end of FB76.2 but was ninety nucleotides longer than FB76.2 at the 5′ end. The additional nucleotides encoded a stop codon beginning at position 47 which was in reading frame with the first methionine in FB76.2 described above (nucleotide 164 in FB93a). The position of the stop codon indicated the presence of a complete open reading frame and that FB76.2 probably represented a full length cDNA. Like FB76.2, FB93a did not contain the 180 nucleotide insert that was present in FB68.2.

[0068] FB94a contained a 1.5 kb cDNA insert and the 3′ end extended almost 0.1 kb beyond the stop codon. The first methionine was encoded beginning at nucleotide 26, and assuming this residue to be the initiating methionine, FB94a encoded a 466 amino acid protein with a predicted molecular weight of 54,367 Da. FB94a differed from FB76.2 and FB93a by absence of a 149 nucleotide region which, if consistent with the sequences for FB76.2 and FB93a, would have been located after nucleotide 42. The absence of the 149 nucleotide sequence produced a putative initiator methionine that is in a different reading frame than that found in FB76.2 and FB93a. Like FB76.2 and FB93a, FB94a did not contain the 180 nucleotide region found in FB68.2.

[0069] A search of the EST data base with the FB94a and FB93a sequences identified yet another possible sequence for a PDE10 cDNA. The sequence of EST A158300 lacked both the 149 nucleotide and the 180 nucleotide sequences discussed above. In addition, A158300 also lacked 55 nucleotides immediately 3′ to the 180 nucleotide region as found in the FB68.2 sequence. The open reading frame in A158300 extended to the 5′ end and the first methionine corresponded to the same one used by FB76.2 and FB93a. The presence of the additional 55 nucleotide deletion from A158300 resulted in a different reading frame for the sequence between the site where the 149 nucleotides were deleted and the site where the 180 nucleotides were deleted.

[0070] The sequence information for PDE10 derived from these cDNA sequences can be summarized as follows. There is a 149 nucleotide sequence found in some clones (sequences FB76.2, FB93a, FB68.2) but not in all (sequences FB94a, A158300). The 149 nucleotide sequence is followed by a 44 nucleotide region that is present in all the PDE10 cDNAs analyzed to date. Following the 44 nucleotide region is a sequence of 235 nucleotides in length. The region can be present in its entirety (as found in the sequence for FB68.2) or without the first 180 nucleotides (as observed in sequences FB76.2 and FB93a). As still another alternative, the whole region can be removed (as found in the sequence for A158300). These possibilities predict six different mRNA structures, four of which have been isolated.

[0071] The presence or absence of the 149 nucleotide region may reflect the presence or absence of an exon, and the presence of all or some of the 235 nucleotide region may reflect alternative 3′ splice acceptor site usage. As an alternative, it is also possible that the 235 nucleotide region represents two separate exons of 180 and 55 nucleotides in length. The presence or absence of the 149 nucleotide sequence alters the reading frame of the encoded protein as does the presence or absence of the 55 nucleotide sequence.

[0072] A number of single nucleotide differences have been observed in comparison of the various PDE10 cDNAs. R00718/9 has a cytosine at nucleotide position 155 whereas the other cDNAs have a thymidine at this position; this difference represented a silent change as proline is encoded by both sequences. R00718/9 also has a cytosine at position 161 whereas the other cDNAs have an adenosine at the same position; this difference also represented a silent change as both sequences encode alanine. FB94a has a guanosine at position 1383 whereas the other cDNAs have an adenosine at this position; as a consequence of the difference, FB94a encodes a glycine rather than a glutamic acid at that position. FB76.2 has an adenosine rather than a cytosine at position 1809; the difference does not effect an amino acid difference since the nucleotide position is located in the 3′ untranslated region. FB79c also has one less adenosine in the string of nucleotides between 1204 and 1215 than do the other cDNAs; this difference is also within the 3′ untranslated region.

[0073] In comparison of a predicted PDE10 amino acid sequence with other known PDEs indicated that most, but not all, of the amino acids that are conserved among the query sequences were also found in PDE10. Comparison of the PDE10 catalytic region to PDE4A, PDE5A, and PDE7A revealed 32%, 30% and 34% identity, respectively.

EXAMPLE 2 Northern Blot

[0074] In order to determine which cell and tissue types express PDE10, Northern blot analysis was carried out using a commercially prepared multi-tissue Northern blot (Clontech, Palo Alto, Calif.). The probe was a EcoRI/Bc/I fragment of the FB76.2 corresponding to nucleotides 1 to 883. Hybridization conditions were as previously described [Loughney et al., supra, (1996)].

[0075] Results indicated a 2.2 to 2.4 kb band which was strongest in kidney, present in heart, pancreas, and placenta, and weakest in brain, lung, skeletal muscle and liver. The band was fairly wide in placenta suggesting that it might contain a number of mRNAs of slightly different sizes.

EXAMPLE 3 Chromosome Mapping

[0076] As mentioned above, the X88347, X88467, and X88465 ESTs were identified with an exon trapping procedure using DNA from chromosome 21 [Chen et al 1996]. X88467 was identified as a new sequence with homology to a mouse calcium-, calmodulin-dependent phosphodiesterase Q01065 aa 52-103. XD88347 was identified to be the same as EST R00718 and similar to Drosophila cAMP dependent phosphodiesterase P12252. Both of these sequences were placed in a category described as having strong homology to known protein sequences.

[0077] A search of the Sequence Tagged Sites (STS) database at NCBI revealed homology of the 3′-end of PDE10 to STS WI-13322 which has been mapped to region 220.72 cr. from the top of chromosome 21. The cDNA that this STS was derived from begins at nucleotide 1899 of FB68.2, does not have the poly A tail and extends further 3′ than FB68.2. It seems likely that this STS sequence represents a PDE10A transcript to which no poly (A⁺) tail has been added or a PDE10A transcript that uses an alternative site for poly (A⁺) addition. STS WI-13322 was placed on a Whitehead map of chromosome 21 near SGC35805, which is derived from the gene for the cystathionine beta-synthase (CBS). CBS has been mapped to chromosome 21 at 21q22.3 [Avramopoulos, et al, Hum. Genet. 90:566-568 (1993); Munke et al., Hum. Genet. 42:550-559 (1988)].

[0078] A number of different genetic diseases map to this region of chromosome 21, for example, Down syndrome [Delabar, et al., Eur. J. Hum. Genet.1:114-124(1993)]. It is not clear that PDE10A falls within the Down syndrome critical region (DSCR) but it is possible that genes elsewhere on chromosome 21 also contribute to Down syndrome [Korenberg, et al., Proc. Natl. Acad. Sci. (USA) 91:4997-5001 (1994)]. As another example, a locus involved in bipolar affective disorder in some families has been mapped to 21q22.3 [Vallada, et al., J. Affect. Disord. 41:217-221 (1996)]. Other examples include Knobloch syndrome, characterized by myopia and retinal degeneration and detachment [Sertie, et al., Hum. Mol. Genet. 5:843-847 (1996)], and one or more genes responsible for congenital recessive deafness (DFNB8, DFNB10) [Veske, et al., Hum. Mol. Genet. 5:165168 (1996); Bonne-Tamir, et al., Am. J. Hum. Genet. 58:1254-1259 (1996)]. PDE10A may play a role in any or all of these disease states.

EXAMPLE 4 Expression and Characterization of PDE10

[0079] The entire open reading frame of the PDE10 cDNA (clone FB94a) was placed into a yeast ADH vector including the alcohol dehydrogenase promoter. The construct was built in two steps.

[0080] The 5′ end was generated using PCR and FB94a DNA as template. PCR was carried out using the 5′ primer below (SEQ ID NO: 25) in combination with 3′ primer R71A3 (SEQ ID NO: 26). The 5′ primer includes an NcoI site (underlined in SEQ ID NO: 25 below) and the initiating methionine codon of FB94a is in bold. The 5′ primer also adds a FLAG® epitope tag (Eastman Kodak, Rochester, N.Y.) to the amino terminus of the encoded protein; the FLAG® tag is an epitope (SEQ ID NO: 24) recognized by the monoclonal antibody M2 (Eastman Kodak). FLAG ® TAG Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys (SEQ ID NO: 24) 5′ Primer TAGACCATGGACTACAAGGACGACGA- (SEQ ID NO: 25) TGACAAGATGGACGCATTCAGAAGCACT R71A3 CGAGGAGTCAACTTCTTG (SEQ ID NO: 26)

[0081] PCR was carried out using 5 μl each primer (100 μg/ml stock), 5 μl 10×X buffer (Perkin Elmer), 5 μl 10×nucleotides (2 mM stock), 3 μl MgCl₂ (25 mM stock), FB94a DNA, and 0.3 μl Taq polymerase (Perkin Elmer) in a reaction volume of 50 μl. After incubating the reaction mixture at 94° C. for four minutes, 30 cycles of one minute at 94° C. two minutes at 50° C., and four minutes at 72° C. were carried out. The PCR product was cleaved with NcoI and HincII and purified using agarose gel electrophoresis. The 3′ sequence of PDE10 was isolated as a HincII/EcoRI fragment cleaved from FB94a and purified by agarose gel electrophoresis. The two fragments were combined and ligated into a NcoI/EcoRI-digested Bluescript® vector (Stratagene, La Jolla, Calif.), previously modified by the insertion of the ADH promoter previously removed from a YEpC-PADH2d vector [Price et al. Meth. Enzymol. 185:308-315 (1990)] as a SacI/NcoI fragment, to generate plasmid PDE10-1. New junctions and sequence generated by PCR were verified by sequencing.

[0082] In the second step of plasmid construction, the SacI/SalI fragment from PDE10-1 containing the ADH promoter and PDE10 open reading frame was purified by two rounds of agarose gel electrophoresis and ligated into SacI/SalI cut YEpC-PADH2 vector.

[0083] Following transformation into BJ2-54, a yeast strain lacking endogenous PDE activity, a colony was selected, streaked out on SC-leu plates and a single colony carrying the PDE10 construct was chosen for further characterization. Following overnight growth in SC-leu media the culture was diluted 1:250 in fresh SC-leu and grown overnight at 30° C. until it reached a density of 10⁷ cells/ml. The cells were collected by centrifugation, washed once with YEP 3% glycerol media, resuspended in YEP containing 3% glycerol, and grown at 30° C. for another 24 hours. The cells were harvested by centrifugation, washed with water, and frozen at −70° C. until use. Prior to use, an aliquot of the yeast extract was analyzed by SDS PAGE. A protein specific to yeast carrying the PDE10 expression construct that migrated on the SDS PAGE gels with the expected mobility (55.5 kDa) was observed by Coomassie blue staining.

[0084] Yeast cells ( 1×10¹⁰) were thawed with 200 μg/ml each of pepstatin A, leupeptin, and aprotinin 1 mM DTT, and 20 μg/ml calpain inhibitors (I and II). Two hundred μl of glass beads (0.5 mm, acid washed) were added, and the mixture was vortexed for eight cycles of 30 seconds each. Samples were cooled for 4.5 minutes at 4° C. between cycles. After lysis, 0.8 ml lysis buffer was added, the lysate separated from the beads, and the lysate centrifuged for 30 minutes at 100,000×g in a Beckman TL-100 tabletop centrifuge. The supernatant was aliquoted, frozen in dry ice/ethanol, and stored at −70° C.

[0085] Kinetic assays were performed on a BIOMEK® 1000 programmable robotic station (Beckman Instruments). The range of final substrate concentration was 0.2 to 1000 μM for cAMP and 0.6-2000 nM for cGMP. The highest nucleotide concentration contained 1 to 1.5 million Cerenkov counts of ³²P-labeled substrate per assay. The enzyme preparation was initially diluted 1:500 (cAMP as substrate) or 1:50,000 (cGMP as substrate). The enzyme dilution buffer consisted of 25 mM Tris-HCl pH 8.9, 5 μM ZnSO₄5 mM MgCl₂, 0.1 mM DTT, 100 mM NaCl and 0.1 mg/ml BSA (Calbiochem; fatty acid free). Activity at each substrate concentration was derived from a linear fit of successive four-fold enzyme dilutions across the plate.

[0086] Assays were performed at 30° C. for 15 minutes. After 12 minutes, 5 μl snake venom from Crotalus atrox (15 mg/ml protein) was added to each reaction. Assays were stopped by addition 200 μl of charcoal suspension (25 mg/ml activated charcoal in 0.1 M monobasic potassium phosphate). The plate was centrifuged at 2600 rpm, and 200 μl of each supernatant was transferred into Microbeta® counting plates and counted on a WALLAC Microbeta® by Cerenkov counting. Data were evaluated with a predesigned Microsoft Excel® Spreadsheet, and the kinetic parameters were fitted to a Michaelis-Menton model using the program Table Curve® from Jandel Scientific.

[0087] Results indicated that the K_(m) for cGMP hydrolysis was 5 (±1) nM and the K_(m) for cAMP hydrolysis was 160 (±30) μM. In the extract, cGMP hydrolytic activity was determined to be 0.035 (±0.01) μmol/min/mg, while cAMP hydrolysis was measured to be 0.52 (±0.06) μmol/min/mg. Thus, although PDE10 had much greater affinity for cGMP, the V_(max) for cAMP was 15-fold greater.

[0088] In order to distinguish PDE10 from other PDE families, a panel of PDE inhibitors with activities against defined PDE families was tested for PDE10 inhibition using cAMP as a substrate. The results of the assay are set out in Table 1 below. TABLE 1 PDE10 Inhibition with Isozyme-specific PDE Inhibitors Target PDE10 Target Family Inhibitor Family IC₅₀ ₍μM) IC₅₀ (μM) SCH46642 PDE1 14 0.2⁵ EHNA PDE2 477 0.8² Cilostamide PDE3 100 0.04-0.9³ Rolipram PDE4 529 0.18-0.5⁴ DMPPO PDE5 9 0.003¹ IBMX non-specific 59  2-20¹

[0089] The results further distinguish PDE10 from PDEs in families 1 through 5 in that specific inhibitors for enzymes in those families are significantly less effective in inhibiting PDE10.

EXAMPLE 5 Production of Anti-PDE10 Antibodies

[0090] A GST fusion protein was produced in E. coli to provide an antigen for generation of monoclonal antibodies to PDE10. An EcoRI fragment from FB76.2 (nucleotides 280 through 1829 in SEQ ID NO: 18) was inserted into the EcoRI site of pGEX3X (Pharmacia) and the resultant construct was transformed in the E. coli strain XL1 Blue. A GST-PDE10 fusion protein including 464 amino acids from PDE10 was expressed from this construct following induction with IPTG. The fusion protein was isolated using SDS-PAGE, the band of appropriate size excised from the gel following staining with cold 0.4 M KCl, and the protein obtained from the acrylamide by electroelution. The elution product was dialyzed against PBS and concentrated using Centriprep 10 and Centricon columns (Amicon, Beverly Mass.) prior to being injected into mice.

[0091] On day 0, four Balb/c mice were pre-bled and immunized by subcutaneous injection with a panel of antigens including 30 μg/mouse GST-PDE10 fusion protein in complete Freund's adjuvant in 200 μl total volume. The same injections were repeated at weeks three and nine in incomplete Freund's adjuvant. Ten days after the last immunization, test bleeds were obtained and screened by antigen capture ELISA and Western analysis.

[0092] In the ELISA, Immulon® 4 plates (Dynex, Cambridge, Mass.) were coated at 4° C. with 50 μl/well of a solution containing 2 μg/ml GST-PDE10 in 50 mM carbonate buffer, pH 9.6. Plates were blocked with 0.5% fish skin gelatin (Sigma) for 30 minutes and 50 μl serum diluted in PBS with 0.5% Tween® 20 (PBST) was added. Serum dilutions ranged from 1:100 to 1:102,400 and were obtained by a series of doubling dilutions. After incubation at 37° C. for 30 minutes and washing three times with PBST, 50 μl of horseradish peroxidase-conjugated goat anti-mouse IgG(fc) antibody (Jackson) (diluted 1:10000 in PBST) was added. Plates were incubated as above and washed four times with PBST. Antibody was detected with addition of tetramethyl benzidine(Sigma Chemical, St. Louis, Mo.) and the color reaction was stopped after five minutes with the addition of 50 μl of 15% H₂SO₄. Absorbance at 450 nM was measured on a plate reader.

[0093] For Western analysis, SDS-PAGE gels were run with approximately 10 μg yeast PDE10 extract and approximately 200 ng of gel-purified GST-PDE10 and the proteins were transferred to Immobilon-PVDF. A standard enhanced chemiluminescence (ECL) Western blot protocol was performed using BioRad goat anti-mouse IgG horseradish peroxidase as the secondary antibody.

[0094] In preparation of hybridomas, splenocytes from mice giving a positive result from the ELISA and/or Western blotting protocols above, were fused to NS-1 cells in a ratio of 5:1 by standard methods using polyethylene glycol 1500 (Boehringer Mannheim) [Harlow and Lane, Antibodies, a Laboratory Manual, Cold Spring Harbor Laboratory, p.211 (1988)]. The fused cells were resuspended in 200 ml RPMI containing 15% FBS, 100 mM sodium hypoxanthine, 0.4 mM aminopterin, 16 mM thymidine (HAT) (Gibco), 25 units/ml IL-6 (Boehringer Mannheim) and 1.5×10⁶ murine thymocytes/ml and dispensed into ten 96-well flat bottom tissue culture plates (Corning, United Kingdom) at 200 μl/well. Cells were fed on days 2, 4, and 6 post fusion by aspirating approximately 100 μl from each well with an 18 G needle (Becton Dickinson) and adding 100 μl/well plating medium described above except containing 10 units/ml IL-6 and lacking thymocytes. On days 9 to 12, supernatants from the fusion wells were screened by antigen capture ELISA using GST and GST-PDE10 and by ECL Western analysis as described above.

[0095] A positive signal of the expected size was obtained on both lanes of the Western blot using mouse blood and monoclonal antibodies with reactivity to the yeast recombinant protein were obtained in the subsequent fusion.

EXAMPLE 6 Analysis of PDE10 Expression by in situ Hybridization

[0096] Expression of PDE10 was examined in tissue sections by in situ hybridization as described below.

[0097] Preparation of Probe

[0098] An EcoRI/PstI restriction enzyme fragment from the cDNA FB93a (corresponding to nucleotides 370 through 978 in SEQ ID NO: 22) was subcloned into a Bluescript® vector (Stratagene, La Jolla, Calif.) to generate an expression plasmid designated PDE10A3A. The plasmid was digested with EcoRI and transcribed with T3 polymerase to generate an antisense probe. A sense probe was generated by digestion the plasmid with BamHI and transcribing with T7 polymerase. The PDE10 templates were transcribed using a RNA Transcription kit (Stratagene, La Jolla, Calif.) in a reaction containing 5 μl of 5×transcription buffer (Stratagene), 30 mM DTT (Stratagene), 0.8 mM each ATP, CTP, GTP (10 mM (Stratagene), 40 U RNase BlockII (Stratagene), 12.5 UT3 or T7 polymerase (Stratagene), and 300 ng linearized plasmid template, 50 μCi³⁵S-UTP (greater than 1000 Ci/mmol, Amersham, Arlington Heights, Ill.). The mixture was incubated at 37° C. for one hour after which the template DNA was removed by addition of 1 μl of RNase-free DNase I (Stratagene) and incubation for 15 minutes at 37° C. The probe was hydrolyzed to approximately 250 nucleotides in length to facilitate tissue penetration by adding 4 μl 1 M NaHCO₃ and 6 μl 1 M Na₂CO₃ for 22 minutes at 60° C. and the reaction mixture was neutralized by addition of 25 μl of a solution containing 100 μl 3 M sodium acetate, 5 μl acetic acid (VWR, So. Plainfield, N.J.), and 395 μl dH₂0. A Quick Spin G50 RNA column (5′→3′ Inc., Boulder, Colo.) was prepared according to the manufacturer's suggested protocol. The probe was placed in the center of the column and the column centrifuged for four minutes at 1,000 rpm in a desk top centrifuge. The column flow-through was mixed with 50 μl dH₂O, 2 μl of a 10 mg/ml tRNA solution, 10 μl 3 M sodium acetate, and 200 μl 100% ethanol (VWR) and the resulting mixture was incubated at −20° C. overnight. The probe solution was microfuged for 15 minutes at 4° C., the supernatant was removed, and the pellet was resuspended in 40 μl 1×TBE containing 1μl of 0.1 M DTT. The probe was stored at −70° C. until the in situ hybridization assay was performed.

[0099] Preparation of Tissue Samples and in situ Hybridization

[0100] Tissues (National Disease Research Interchange, Philadelphia, Pa. and Cooperative Human Tissue Network, Philadelphia, Pa.) were sectioned at 6 μm and placed on Superfrost Plus slides (VWR). Sections were fixed for 20 minutes at 4° C. in 4% paraformaldehyde (Sigma, St. Louis, Mo.). The slides were rinsed in three changes of 1×calcium-, magnesium-free phosphate buffered saline (CMF-PBS), dehydrated with three successive washes with 70% ethanol, 95% ethanol and 100% ethanol, and dried for 30 minutes at room temperature. The slides were placed in 70% formamide (J. T. Baker) in 2×SSC for two minutes at 70° C., rinsed in 2×SSC at 4° C., dehydrated through 70%, 95% and 100% ethanol washes, and dried for 30 minutes at room temperature.

[0101] A prehybridization step was performed by placing the slides in an airtight box containing a piece of filter paper saturated with buffer containing 50% formamide (J. T. Baker) in 4×SSC. Each section was covered with 100 μl of rHB2 buffer consisting of 10% dextran sulfate (Sigma), 50% formamide (J. T. Baker, Phillpsburg, N.J.), 100 mM DTT (Boehringer Mannheim, Indianapolis, Ind.), 0.3 M NaCl (Sigma), 20 mM Tris, pH 7.5, 5 mM EDTA (Sigma), and 1×Denhardt's solution (Sigma) and the slides were incubated at 42° C. for two hours. The probe, as described above, was prepared by mixing 4×10⁵ cpm/tissue section with 5 μl of a 10 mg/ml tRNA solution per section and heating the mixture at 95° C. for three minutes. Ice cold rHB2 buffer was added to bring the final volume to 20 μl/section. The probe-containing solution (20 μl/section) was added to 100 μl rHB2 buffer previously applied. The slides were incubated at 55° C. for 12 to 16 hours. Following hybridization, the slides were washed once in 4×SSC containing 10 mM DTT for one hour at room temperature, once in 50% deionized formamide (J. T. Baker), 1×SSC, and 1 mM DTT for 40 minutes at 60° C., once in 2×SSC for 30 minutes at room temperature, and once in 0.1×SSC for 30 minutes at room temperature. The sections were dehydrated through 70%, 95%, and 100% ethanol washes and air dried for 30 minutes. The slides were dipped in Kodak NTB2 nuclear emulsion, dried for one to three hours at room temperature in the dark, and stored in the dark at 4° C. with desiccant until time of development. The slides were developed in 4° C. Kodak Dektol® developer for two minutes, dipped four times in 4° C. dH₂O, and placed in 4° C. Kodak fixer for ten minutes. The slides were rinsed in dH₂O and a standard hematoxylin and eosin (H&E) stain was performed as follows.

[0102] The slides were rinsed in dH₂O and stained with hematoxylin and eosin by transfer of the slides through a series of the following steps: five minutes in formaldehyde/alcohol (100 ml formaldehyde, 900 ml 80% ethanol); three rinses in water for a total of two minutes; five minutes in 0.75% Harris hematoxylin (Sigma); three rinses in water for a total of two minutes; one dip in 1% HCl/50% ethanol; one rinse in water; four dips in 1% lithium carbonate; ten minutes in tap water; two minutes in 0.5% eosin (Sigma); three rinses in water for a total of two minutes; two minutes in 70% ethanol; three one-minute rinses in 95% ethanol; two one-minute rinses in 100% ethanol; and two two-minute rinses in xylene. Slides were mounted with cytoseal 60 (Stephens Scientific, Riverdale, N.J.).

[0103] The signals obtained with an antisense PDE10 probe were compared to the control signals generated by a sense PDE10 probe and any signal specific to the antisense probe was assumed to represent PDE10 expression. PDE10 signal was detected throughout much of the cerebellum, with very strong signal in the Purkinje cells.

EXAMPLE 7 High Throughput Screening for PDE10 Inhibitors

[0104] In an attempt to identify specific inhibitors, PDE10 was screened against a chemical library containing compounds of known structure. Initial screening was performed on pools of compounds (22 compounds per pool) with each compound present at 4.6 μM. Pools which inhibited PDE10 activity by greater than 50% were selected and the individual compounds in the pool were screened at a concentration of 20 μM. IC₅₀ values were determined for compounds that inhibited enzyme activity.

[0105] An extract was prepared from Saccharomyces cerevisiae strain BJ2-54 (described in Example 4) lacking endogenous PDE activity and having PDE10 at an activity of 49 nmol cGMP hydrolyzed/min/ml with 32 nM cGMP. The extract was diluted 1:21,000-fold for use in the assay. Dilution buffer included 25 mM Tris, pH 8.0, 0.1 mM DTT, 5.0 mM MgCl₂, 100 mM NaCl, 5 μM ZnSO₄ and 100 μg/ml BSA. PDE assay buffer (5×) contained 200 mM Tris, pH 8.0, 5 mM EGTA, 25 mM MgCl₂ and 0.5 mg/ml BSA. Just prior to screening, 5×PDE assay buffer, deionized water, and 5′-nucleosidase (stock solution 15 mg/ml snake venom 5-nucleosidase in 20 mM Tris, pH 8.0) were mixed at ratios of 4:4:1 to make Assay Reagent Mix.

[0106] A Packard MultiPROBE® was used to add 45 μl of the Assay Reagent Mix and 20 μl of the chemical compound pools. A BIOMEK® 1000 (See Example 4) was used to add 20 μl of PDE10 extract diluted as described above and 20 μl ³²P-cGMP (ICN, specific activity 250 μCi/mmol, diluted to 0.4 μCi/ml, 16 nM, in deionized water). Final cGMP concentration in the assay was 0.08 μl Ci/ml, 3.2 nM. Ten minutes after addition of ³²P-cGMP, 140 μl of 25 mg/ml charcoal (in 0.1 μM NaH₂PO₄) was added to stop the reaction. After a 20 minute incubation at room temperature, the assay plates were centrifuged for five minutes at 3,500 rpm in a Beckman GS-6R centrifuge. A BIOMEK® 1000 was used to transfer 140 μl of the supernatant to a Wallac counting plate and Cerenkov radiation was measured in a Wallac MicroBeta Counter.

[0107] Several compounds that merit further investigation were found to inhibit enzyme activity.

[0108] Numerous modifications and variations in the invention as set forth in the above illustrative examples are expected to occur to those skilled in the art. Consequently only such limitations as appear in the appended claims should be placed on the invention.

1 26 1 1548 DNA Homo sapiens CDS (26)..(1423) 1 cccaaggcca tctacctgga catcg atg gac gca ttc aga agc act ccg tac 52 Met Asp Ala Phe Arg Ser Thr Pro Tyr 1 5 aaa gtg aga cct gtg gcc atc aag caa ctc tcc gag aga gaa gaa tta 100 Lys Val Arg Pro Val Ala Ile Lys Gln Leu Ser Glu Arg Glu Glu Leu 10 15 20 25 atc cag agc gtg ctg gcg cag gtt gca gag cag ttc tca aga gca ttc 148 Ile Gln Ser Val Leu Ala Gln Val Ala Glu Gln Phe Ser Arg Ala Phe 30 35 40 aaa atc aat gaa ctg aaa gct gaa gtt gca aat cac ttg gct gtc cta 196 Lys Ile Asn Glu Leu Lys Ala Glu Val Ala Asn His Leu Ala Val Leu 45 50 55 gag aaa cgc gtg gaa ttg gaa gga cta aaa gtg gtg gag att gag aaa 244 Glu Lys Arg Val Glu Leu Glu Gly Leu Lys Val Val Glu Ile Glu Lys 60 65 70 tgc aag agt gac att aag aag atg agg gag gag ctg gcg gcc aga agc 292 Cys Lys Ser Asp Ile Lys Lys Met Arg Glu Glu Leu Ala Ala Arg Ser 75 80 85 agc agg acc aac tgc ccc tgt aag tac agt ttt ttg gat aac cac aag 340 Ser Arg Thr Asn Cys Pro Cys Lys Tyr Ser Phe Leu Asp Asn His Lys 90 95 100 105 aag ttg act cct cga cgc gat gtt ccc act tac ccc aag tac ctg ctc 388 Lys Leu Thr Pro Arg Arg Asp Val Pro Thr Tyr Pro Lys Tyr Leu Leu 110 115 120 tct cca gag acc atc gag gcc ctg cgg aag ccg acc ttt gac gtc tgg 436 Ser Pro Glu Thr Ile Glu Ala Leu Arg Lys Pro Thr Phe Asp Val Trp 125 130 135 ctt tgg gag ccc aat gag atg ctg agc tgc ctg gag cac atg tac cac 484 Leu Trp Glu Pro Asn Glu Met Leu Ser Cys Leu Glu His Met Tyr His 140 145 150 gac ctc ggg ctg gtc agg gac ttc agc atc aac cct gtc acc ctc agg 532 Asp Leu Gly Leu Val Arg Asp Phe Ser Ile Asn Pro Val Thr Leu Arg 155 160 165 agg tgg ctg ttc tgc gtc cac gac aac tac aga aac aac ccc ttc cac 580 Arg Trp Leu Phe Cys Val His Asp Asn Tyr Arg Asn Asn Pro Phe His 170 175 180 185 aac ttc cgg cac tgc ttc tgc gtg gcc cag atg atg tac agc atg gtc 628 Asn Phe Arg His Cys Phe Cys Val Ala Gln Met Met Tyr Ser Met Val 190 195 200 tgg ctc tgc agt ctc cag gag aag ttc tca caa acg gat atc ctg atc 676 Trp Leu Cys Ser Leu Gln Glu Lys Phe Ser Gln Thr Asp Ile Leu Ile 205 210 215 cta atg aca gcg gcc atc tgc cac gat ctg gac cat ccc ggc tac aac 724 Leu Met Thr Ala Ala Ile Cys His Asp Leu Asp His Pro Gly Tyr Asn 220 225 230 aac acg tac cag atc aat gcc cgc aca gag ctg gcg gtc cgc tac aat 772 Asn Thr Tyr Gln Ile Asn Ala Arg Thr Glu Leu Ala Val Arg Tyr Asn 235 240 245 gac atc tca ccg ctg gag aac cac cac tgc gcc gtg gcc ttc cag atc 820 Asp Ile Ser Pro Leu Glu Asn His His Cys Ala Val Ala Phe Gln Ile 250 255 260 265 ctc gcc gag cct gag tgc aac atc ttc tcc aac atc cca cct gat ggg 868 Leu Ala Glu Pro Glu Cys Asn Ile Phe Ser Asn Ile Pro Pro Asp Gly 270 275 280 ttc aag cag atc cga cag gga atg atc aca tta atc ttg gcc act gac 916 Phe Lys Gln Ile Arg Gln Gly Met Ile Thr Leu Ile Leu Ala Thr Asp 285 290 295 atg gca aga cat gca gaa att atg gat tct ttc aaa gag aaa atg gag 964 Met Ala Arg His Ala Glu Ile Met Asp Ser Phe Lys Glu Lys Met Glu 300 305 310 aat ttt gac tac agc aac gag gag cac atg acc ctg ctg aag atg att 1012 Asn Phe Asp Tyr Ser Asn Glu Glu His Met Thr Leu Leu Lys Met Ile 315 320 325 ttg ata aaa tgc tgt gat atc tct aac gag gtc cgt cca atg gaa gtc 1060 Leu Ile Lys Cys Cys Asp Ile Ser Asn Glu Val Arg Pro Met Glu Val 330 335 340 345 gca gag cct tgg gtg gac tgt tta tta gag gaa tat ttt atg cag agc 1108 Ala Glu Pro Trp Val Asp Cys Leu Leu Glu Glu Tyr Phe Met Gln Ser 350 355 360 gac cgt gag aag tca gaa ggc ctt cct gtg gca ccg ttc atg gac cga 1156 Asp Arg Glu Lys Ser Glu Gly Leu Pro Val Ala Pro Phe Met Asp Arg 365 370 375 gac aaa gtg acc aag gcc aca gcc cag att ggg ttc atc aag ttt gtc 1204 Asp Lys Val Thr Lys Ala Thr Ala Gln Ile Gly Phe Ile Lys Phe Val 380 385 390 ctg atc cca atg ttt gaa aca gtg acc aag ctc ttc ccc atg gtt gag 1252 Leu Ile Pro Met Phe Glu Thr Val Thr Lys Leu Phe Pro Met Val Glu 395 400 405 gag atc atg ctg cag cca ctt tgg gaa tcc cga gat cgc tac gag gag 1300 Glu Ile Met Leu Gln Pro Leu Trp Glu Ser Arg Asp Arg Tyr Glu Glu 410 415 420 425 ctg aag cgg ata gat gac gcc atg aaa gag tta cag aag aag act gac 1348 Leu Lys Arg Ile Asp Asp Ala Met Lys Glu Leu Gln Lys Lys Thr Asp 430 435 440 agc ttg acg tct ggg gcc acc gag aag tcc aga ggg aga agc aga gat 1396 Ser Leu Thr Ser Gly Ala Thr Glu Lys Ser Arg Gly Arg Ser Arg Asp 445 450 455 gtg aaa aac agt gaa gga gac tgt gcc tgaggaaagc ggggggcgtg 1443 Val Lys Asn Ser Glu Gly Asp Cys Ala 460 465 ctgcagttc tggacgggct ggccgagctg cgcgggatcc ttgtgcaggg aagagctgcc 1503 ctgggcacct ggcaccacaa gaccatgttt tctaagaacc atttt 1548 2 466 PRT Homo sapiens 2 Met Asp Ala Phe Arg Ser Thr Pro Tyr Lys Val Arg Pro Val Ala Ile 1 5 10 15 Lys Gln Leu Ser Glu Arg Glu Glu Leu Ile Gln Ser Val Leu Ala Gln 20 25 30 Val Ala Glu Gln Phe Ser Arg Ala Phe Lys Ile Asn Glu Leu Lys Ala 35 40 45 Glu Val Ala Asn His Leu Ala Val Leu Glu Lys Arg Val Glu Leu Glu 50 55 60 Gly Leu Lys Val Val Glu Ile Glu Lys Cys Lys Ser Asp Ile Lys Lys 65 70 75 80 Met Arg Glu Glu Leu Ala Ala Arg Ser Ser Arg Thr Asn Cys Pro Cys 85 90 95 Lys Tyr Ser Phe Leu Asp Asn His Lys Lys Leu Thr Pro Arg Arg Asp 100 105 110 Val Pro Thr Tyr Pro Lys Tyr Leu Leu Ser Pro Glu Thr Ile Glu Ala 115 120 125 Leu Arg Lys Pro Thr Phe Asp Val Trp Leu Trp Glu Pro Asn Glu Met 130 135 140 Leu Ser Cys Leu Glu His Met Tyr His Asp Leu Gly Leu Val Arg Asp 145 150 155 160 Phe Ser Ile Asn Pro Val Thr Leu Arg Arg Trp Leu Phe Cys Val His 165 170 175 Asp Asn Tyr Arg Asn Asn Pro Phe His Asn Phe Arg His Cys Phe Cys 180 185 190 Val Ala Gln Met Met Tyr Ser Met Val Trp Leu Cys Ser Leu Gln Glu 195 200 205 Lys Phe Ser Gln Thr Asp Ile Leu Ile Leu Met Thr Ala Ala Ile Cys 210 215 220 His Asp Leu Asp His Pro Gly Tyr Asn Asn Thr Tyr Gln Ile Asn Ala 225 230 235 240 Arg Thr Glu Leu Ala Val Arg Tyr Asn Asp Ile Ser Pro Leu Glu Asn 245 250 255 His His Cys Ala Val Ala Phe Gln Ile Leu Ala Glu Pro Glu Cys Asn 260 265 270 Ile Phe Ser Asn Ile Pro Pro Asp Gly Phe Lys Gln Ile Arg Gln Gly 275 280 285 Met Ile Thr Leu Ile Leu Ala Thr Asp Met Ala Arg His Ala Glu Ile 290 295 300 Met Asp Ser Phe Lys Glu Lys Met Glu Asn Phe Asp Tyr Ser Asn Glu 305 310 315 320 Glu His Met Thr Leu Leu Lys Met Ile Leu Ile Lys Cys Cys Asp Ile 325 330 335 Ser Asn Glu Val Arg Pro Met Glu Val Ala Glu Pro Trp Val Asp Cys 340 345 350 Leu Leu Glu Glu Tyr Phe Met Gln Ser Asp Arg Glu Lys Ser Glu Gly 355 360 365 Leu Pro Val Ala Pro Phe Met Asp Arg Asp Lys Val Thr Lys Ala Thr 370 375 380 Ala Gln Ile Gly Phe Ile Lys Phe Val Leu Ile Pro Met Phe Glu Thr 385 390 395 400 Val Thr Lys Leu Phe Pro Met Val Glu Glu Ile Met Leu Gln Pro Leu 405 410 415 Trp Glu Ser Arg Asp Arg Tyr Glu Glu Leu Lys Arg Ile Asp Asp Ala 420 425 430 Met Lys Glu Leu Gln Lys Lys Thr Asp Ser Leu Thr Ser Gly Ala Thr 435 440 445 Glu Lys Ser Arg Gly Arg Ser Arg Asp Val Lys Asn Ser Glu Gly Asp 450 455 460 Cys Ala 465 3 225 DNA Homo sapiens misc_feature 130 N = A, T, G, or C 3 agcgaccgtg agaagtcaga aggccttcct gtggaaccgt tcatggaccg agacaaagtg 60 accaaggcca cagcccagat tgggttcatc aagtttgccc tgatcccaat gtttgaaaca 120 gtgaccaagn tcttccccat ggttgaggag atcatgctgc agccactttg ggaatcccga 180 gatcgntacg aggagctgaa gcggntagat gacgccatga aagag 225 4 158 DNA Homo sapiens misc_feature 12 N = A, T, G, or C 4 gtaccagatc antgcccgca cagagctggc ggtccgntac aatgacatct caccgttgga 60 gnaaccacca ctgcgccgtg gccttccaga tcctcgccga gcctgagtgn aacatcttct 120 ccaacatccc acctgatggg ttcaagcaga tccgacag 158 5 98 DNA Homo sapiens misc_feature 14 N = A, T, G, or C 5 gagaacacca ctgngccgtg gncttccaga tcctcgccga gcctgagtgn aacatcttct 60 ccaacatccc acctgatggg ttcaagcaga tccgacag 98 6 418 DNA Homo sapiens misc_feature 1 N = A, T, G, or C 6 nggttaactg gcgcatcttg tctttctctg agaacagcga tctggttatg gggcatttct 60 gtctctaatg tcactgtctg ctgcattccc tgcagagcga ccgtgagaag tcagaaggcc 120 ttcccgtggc cccgttcatg gaccgagaca aagtgaccaa ggccacagcc caggattggg 180 tttcatcaag tttgtcctga tcccaatgtt tgaaacagtg accaagctct tccccatggg 240 ttgagggaga ttcatgctgg cagccanttt ggggaatccc gaggattcgc tacgagggag 300 cttgaagcgg gattaggatg gacggccatg gaaaggagtt ttacaggaag gnaggatttg 360 acagttttga agttttgggg gggccaccga ggaagttccn ggaggaggag naggcaga 418 7 428 DNA Homo sapiens misc_feature 1 N = A, T, G, or C 7 nagaaaaaag tgaacaaaat ggttcttaga aaacatggtc ttgtggtgcc aggtgcccag 60 gagctcttc cctgcacaag gntcccgcgc antcggccag cccgtccaga actgcagcca 120 cgccccccgn tttcctcagg cacagtctcc ttcactgttt ttcacatctc tgcttctctc 180 tctggacttc tcggtggccc cagacgtcaa gctgtcagtc ttcttctgta actctttcat 240 gggcgtcatc tatccgcttc agctcctcgt aggcgatctc ggggattccc aaagtgggct 300 gcagcatgat cttcctcaac catggggggg aggagcttgg ggcactngtt ttcaaaaatt 360 gggggatcag gggacaaact ttgattggan cccatnttgg ggcttttggg cctttggggc 420 aatttttg 428 8 438 DNA Homo sapiens misc_feature 63 N = A, T, G, or C 8 tttttttttt ttttttttgt atcagtgaac aaaatggttc ttagaaaaca tggtcttgtg 60 gtnccaggtg cccagggagc tcttccctgc acaaggancc cgcgcantcg gccagcccgt 120 ccagaactgc agccacgccc cccgttttcc tcaggcacag tctccttcac tgtttttcac 180 atctctgntt ctctctctgg ganttntcgg tgggccccag aacgtcaagc tgtcagtntt 240 cttctgtaac tntttcatgg gcgtcatcta tccgtttcag cttcctcgta ggcgatnttg 300 gggattccca aagtgggctg gcagcatgga tcttcctcaa accatggggg gaaggagttt 360 gggtcaattn ttttcaaaac attgggggnt cagggacaaa attttgatgg aaacccaatt 420 tgggggntgt gggccttg 438 9 262 DNA Mus musculus 9 gagaattttg actacagcaa cgaggagcac ctgaccctgc tgaagatgat tctcataaaa 60 tgctgtgata tctccaatga agtccgtccc atggaggtgg cagaatcgtg ggtggactgt 120 ttactggaag aatattttat gcagagtgac cgtgagaagt ccgaagcctt cctgtggccc 180 cattcatgga ccgagacaaa gtgaccaaag caacagccca aattgggttc atcaagtttg 240 tcctgatccc aatgtttgaa ac 262 10 250 DNA Mus musculus 10 gagaattttg actacagcaa cgaggagcac ctgaccctgc tgaagatgat tctcataaaa 60 tgctgtgata tctccaatga agtccgtccc atggaggtgg cagaatcgtg ggtggactgt 120 ttactggaag aatattttat gcagagtgac cgtgagaagt ccgaagcctt cctgtggccc 180 attcatggac cgagacaaag tgaccaaagc aacagccaaa ttgggttcat caagtttgtc 240 tgtccaatgt 250 11 459 DNA Homo sapiens misc_feature 155 N = A, T, G, or C 11 attaatcttg gccactgaca tggcaagaca tgcagaaatt atggattctt tcaaagagaa 60 aatggagaat tttgactaca gcaacgagga gcacatgacc ctggtgagtg gcttattctg 120 cctgggtggg cagccaggcg gttgggctgg cgaanaggtt catccatcca gctcacactg 180 gaagccaaga agctgaaatt attagtcttc ttggaacaag gtgtctataa atctggtttt 240 caaggtcatg actcttacta ggaaagtccg ggcagggcct ccctcctgat gggtcctcct 300 tcatggtcag aggcagcatt ctcccattcc tccatctctt ttgggatttt gaaggagata 360 aagtggggtg aaggccgtgc attctcgctc tgnttttcca gagaattaaa accagttttc 420 ccttgaaggc acagccccag cntggcattt tgaaagttg 459 12 599 DNA Homo sapiens CDS (99)..(443) 12 tggccctcga ggccaagaat tcggcacgag tggttaactg gcgcatcttg tctttctctg 60 agaacagcga tctggttatg gggcatttct gtctctaa tgt cac tgt ctg ctg cat 116 Cys His Cys Leu Leu His 1 5 tcc ctg cag agc gac cgt gag aag tca gaa ggc ctt ccc gtg gcc ccg 164 Ser Leu Gln Ser Asp Arg Glu Lys Ser Glu Gly Leu Pro Val Ala Pro 10 15 20 ttc atg gac cga gac aaa gtg acc aag gcc aca gcc cag att ggg ttc 212 Phe Met Asp Arg Asp Lys Val Thr Lys Ala Thr Ala Gln Ile Gly Phe 25 30 35 atc aag ttt gtc ctg atc cca atg ttt gaa aca gtg acc aag ctc ttc 260 Ile Lys Phe Val Leu Ile Pro Met Phe Glu Thr Val Thr Lys Leu Phe 40 45 50 ccc atg gtt gag gag atc atg ctg cag cca ctt tgg gaa tcc cga gat 308 Pro Met Val Glu Glu Ile Met Leu Gln Pro Leu Trp Glu Ser Arg Asp 55 60 65 70 cgc tac gag gag ctg aag cgg ata gat gac gcc atg aaa gag tta cag 356 Arg Tyr Glu Glu Leu Lys Arg Ile Asp Asp Ala Met Lys Glu Leu Gln 75 80 85 aag aag act gac agc ttg acg tct ggg gcc acc gag aag tcc aga gag 404 Lys Lys Thr Asp Ser Leu Thr Ser Gly Ala Thr Glu Lys Ser Arg Glu 90 95 100 aga agc aga gat gtg aaa aac agt gaa gga gac tgt gcc tgaggaaagc 453 Arg Ser Arg Asp Val Lys Asn Ser Glu Gly Asp Cys Ala 105 110 115 ggggggcgtg gctgcagttc tggacgggct ggccgagctg cgcgggatcc ttgtgcaggg 513 aagagctgcc ctgggcacct ggcaccacaa gaccatgttt tctaagaacc attttgttca 573 ctgatacaaa aaaaaaaaaa aaaaaa 599 13 115 PRT Homo sapiens 13 Cys His Cys Leu Leu His Ser Leu Gln Ser Asp Arg Glu Lys Ser Glu 1 5 10 15 Gly Leu Pro Val Ala Pro Phe Met Asp Arg Asp Lys Val Thr Lys Ala 20 25 30 Thr Ala Gln Ile Gly Phe Ile Lys Phe Val Leu Ile Pro Met Phe Glu 35 40 45 Thr Val Thr Lys Leu Phe Pro Met Val Glu Glu Ile Met Leu Gln Pro 50 55 60 Leu Trp Glu Ser Arg Asp Arg Tyr Glu Glu Leu Lys Arg Ile Asp Asp 65 70 75 80 Ala Met Lys Glu Leu Gln Lys Lys Thr Asp Ser Leu Thr Ser Gly Ala 85 90 95 Thr Glu Lys Ser Arg Glu Arg Ser Arg Asp Val Lys Asn Ser Glu Gly 100 105 110 Asp Cys Ala 115 14 28 DNA Artificial Sequence Description of Artificial Sequence primer 14 agtcgaattc accgtgagaa gtcagaag 28 15 28 DNA Artificial Sequence Description of Artificial Sequence primer 15 gtcaaagctt acatggtctt gtggtgcc 28 16 1303 DNA Homo sapiens CDS (107)..(1066) 16 agtgactcta ctttgtgaaa atgtgaaact tcgtgtaggt actcagtaaa tcagtaaatt 60 cttactaacg ttagccccca gcctagctat ggagggtgca tgctga gcc ctg gag 115 Ala Leu Glu 1 cac atg tac cac gac ctc ggg ctg gtc agg gac ttc agc atc aac cct 163 His Met Tyr His Asp Leu Gly Leu Val Arg Asp Phe Ser Ile Asn Pro 5 10 15 gtc acc ctc agg agg tgg ctg ttc tgc gtc cac gac aac tac aga aac 211 Val Thr Leu Arg Arg Trp Leu Phe Cys Val His Asp Asn Tyr Arg Asn 20 25 30 35 aac ccc ttc cac aac ttc cgg cac tgc ttc tgc gtg gcc cag atg atg 259 Asn Pro Phe His Asn Phe Arg His Cys Phe Cys Val Ala Gln Met Met 40 45 50 tac agc atg gtc tgg ctc tgc agt ctc cag gag aag ttc tca caa acg 307 Tyr Ser Met Val Trp Leu Cys Ser Leu Gln Glu Lys Phe Ser Gln Thr 55 60 65 gat atc ctg atc cta atg aca gcg gcc atc tgc cac gat ctg gac cat 355 Asp Ile Leu Ile Leu Met Thr Ala Ala Ile Cys His Asp Leu Asp His 70 75 80 ccc ggc tac aac aac acg tac cag atc aat gcc cgc aca gag ctg gcg 403 Pro Gly Tyr Asn Asn Thr Tyr Gln Ile Asn Ala Arg Thr Glu Leu Ala 85 90 95 gtc cgc tac aat gac atc tca ccg ctg gag aac cac cac tgc gcc gtg 451 Val Arg Tyr Asn Asp Ile Ser Pro Leu Glu Asn His His Cys Ala Val 100 105 110 115 gcc ttc cag atc ctc gcc gag cct gag tgc aac atc ttc tcc aac atc 499 Ala Phe Gln Ile Leu Ala Glu Pro Glu Cys Asn Ile Phe Ser Asn Ile 120 125 130 cca cct gat ggg ttc aag cag atc cga cag gga atg atc aca tta atc 547 Pro Pro Asp Gly Phe Lys Gln Ile Arg Gln Gly Met Ile Thr Leu Ile 135 140 145 ttg gcc act gac atg gca aga cat gca gaa att atg gat tct ttc aaa 595 Leu Ala Thr Asp Met Ala Arg His Ala Glu Ile Met Asp Ser Phe Lys 150 155 160 gag aaa atg gag aat ttt gac tac agc aac gag gag cac atg acc ctg 643 Glu Lys Met Glu Asn Phe Asp Tyr Ser Asn Glu Glu His Met Thr Leu 165 170 175 ctg aag atg att ttg ata aaa tgc tgt gat atc tct aac gag gtc cgt 691 Leu Lys Met Ile Leu Ile Lys Cys Cys Asp Ile Ser Asn Glu Val Arg 180 185 190 195 cca atg gaa gtc gca gag cct tgg gtg gac tgt tta tta gag gaa tat 739 Pro Met Glu Val Ala Glu Pro Trp Val Asp Cys Leu Leu Glu Glu Tyr 200 205 210 ttt atg cag agc gac cgt gag aag tca gaa ggc ctt cct gtg gca ccg 787 Phe Met Gln Ser Asp Arg Glu Lys Ser Glu Gly Leu Pro Val Ala Pro 215 220 225 ttc atg gac cga gac aaa gtg acc aag gcc aca gcc cag att ggg ttc 835 Phe Met Asp Arg Asp Lys Val Thr Lys Ala Thr Ala Gln Ile Gly Phe 230 235 240 atc aag ttt gtc ctg atc cca atg ttt gaa aca gtg acc aag ctc ttc 883 Ile Lys Phe Val Leu Ile Pro Met Phe Glu Thr Val Thr Lys Leu Phe 245 250 255 ccc atg gtt gag gag atc atg ctg cag cca ctt tgg gaa tcc cga gat 931 Pro Met Val Glu Glu Ile Met Leu Gln Pro Leu Trp Glu Ser Arg Asp 260 265 270 275 cgc tac gag gag ctg aag cgg ata gat gac gcc atg aaa gag tta cag 979 Arg Tyr Glu Glu Leu Lys Arg Ile Asp Asp Ala Met Lys Glu Leu Gln 280 285 290 aag aag act gac agc ttg acg tct ggg gcc acc gag aag tcc aga gag 1027 Lys Lys Thr Asp Ser Leu Thr Ser Gly Ala Thr Glu Lys Ser Arg Glu 295 300 305 aga agc aga gat gtg aaa aac agt gaa gga gac tgt gcc tgaggaaagc 1076 Arg Ser Arg Asp Val Lys Asn Ser Glu Gly Asp Cys Ala 310 315 320 ggggggcgtg gctgcagttc tggacgggct ggccgagctg cgcgggatcc ttgtgcaggg 1136 aagagctgcc ctgggcacct ggcaccacaa gaccatgttt tctaagaacc attttgttca 1196 ctgatacaaa aaaaaaaaag gaattcatga tgctgtacag aattttattt ttaaactgtc 1256 ttttaaataa tatattctta tacggaaaaa aaaaaaaaaa aaaaaaa 1303 17 320 PRT Homo sapiens 17 Ala Leu Glu His Met Tyr His Asp Leu Gly Leu Val Arg Asp Phe Ser 1 5 10 15 Ile Asn Pro Val Thr Leu Arg Arg Trp Leu Phe Cys Val His Asp Asn 20 25 30 Tyr Arg Asn Asn Pro Phe His Asn Phe Arg His Cys Phe Cys Val Ala 35 40 45 Gln Met Met Tyr Ser Met Val Trp Leu Cys Ser Leu Gln Glu Lys Phe 50 55 60 Ser Gln Thr Asp Ile Leu Ile Leu Met Thr Ala Ala Ile Cys His Asp 65 70 75 80 Leu Asp His Pro Gly Tyr Asn Asn Thr Tyr Gln Ile Asn Ala Arg Thr 85 90 95 Glu Leu Ala Val Arg Tyr Asn Asp Ile Ser Pro Leu Glu Asn His His 100 105 110 Cys Ala Val Ala Phe Gln Ile Leu Ala Glu Pro Glu Cys Asn Ile Phe 115 120 125 Ser Asn Ile Pro Pro Asp Gly Phe Lys Gln Ile Arg Gln Gly Met Ile 130 135 140 Thr Leu Ile Leu Ala Thr Asp Met Ala Arg His Ala Glu Ile Met Asp 145 150 155 160 Ser Phe Lys Glu Lys Met Glu Asn Phe Asp Tyr Ser Asn Glu Glu His 165 170 175 Met Thr Leu Leu Lys Met Ile Leu Ile Lys Cys Cys Asp Ile Ser Asn 180 185 190 Glu Val Arg Pro Met Glu Val Ala Glu Pro Trp Val Asp Cys Leu Leu 195 200 205 Glu Glu Tyr Phe Met Gln Ser Asp Arg Glu Lys Ser Glu Gly Leu Pro 210 215 220 Val Ala Pro Phe Met Asp Arg Asp Lys Val Thr Lys Ala Thr Ala Gln 225 230 235 240 Ile Gly Phe Ile Lys Phe Val Leu Ile Pro Met Phe Glu Thr Val Thr 245 250 255 Lys Leu Phe Pro Met Val Glu Glu Ile Met Leu Gln Pro Leu Trp Glu 260 265 270 Ser Arg Asp Arg Tyr Glu Glu Leu Lys Arg Ile Asp Asp Ala Met Lys 275 280 285 Glu Leu Gln Lys Lys Thr Asp Ser Leu Thr Ser Gly Ala Thr Glu Lys 290 295 300 Ser Arg Glu Arg Ser Arg Asp Val Lys Asn Ser Glu Gly Asp Cys Ala 305 310 315 320 18 1887 DNA Homo sapiens CDS (74)..(1672) 18 ctcccccgcc tcccgcggcg gctggcgtcg ggaaagtaca gtaaaaagtc cgagtgcagc 60 cgccgggcgc agg atg gga tcc ggc tcc tcc agc tac cgg ccc aag gcc 109 Met Gly Ser Gly Ser Ser Ser Tyr Arg Pro Lys Ala 1 5 10 atc tac ctg gac atc gat gga cgc att cag aag gta atc ttc agc aag 157 Ile Tyr Leu Asp Ile Asp Gly Arg Ile Gln Lys Val Ile Phe Ser Lys 15 20 25 tac tgc aac tcc agc gac atc atg gac ctg ttc tgc atc gcc acc ggc 205 Tyr Cys Asn Ser Ser Asp Ile Met Asp Leu Phe Cys Ile Ala Thr Gly 30 35 40 ctg cct cgg aac acg acc atc tcc ctg ctg acc acc gac gac gcc atg 253 Leu Pro Arg Asn Thr Thr Ile Ser Leu Leu Thr Thr Asp Asp Ala Met 45 50 55 60 gtc tcc atc gac ccc acc atg ccc gcg aat tca gaa cgc act ccg tac 301 Val Ser Ile Asp Pro Thr Met Pro Ala Asn Ser Glu Arg Thr Pro Tyr 65 70 75 aaa gtg aga cct gtg gcc atc aag caa ctc tcc gag aga gaa gaa tta 349 Lys Val Arg Pro Val Ala Ile Lys Gln Leu Ser Glu Arg Glu Glu Leu 80 85 90 atc cag agc gtg ctg gcg cag gtt gca gag cag ttc tca aga gca ttc 397 Ile Gln Ser Val Leu Ala Gln Val Ala Glu Gln Phe Ser Arg Ala Phe 95 100 105 aaa atc aat gaa ctg aaa gct gaa gtt gca aat cac ttg gct gtc cta 445 Lys Ile Asn Glu Leu Lys Ala Glu Val Ala Asn His Leu Ala Val Leu 110 115 120 gag aaa cgc gtg gaa ttg gaa gga cta aaa gtg gtg gag att gag aaa 493 Glu Lys Arg Val Glu Leu Glu Gly Leu Lys Val Val Glu Ile Glu Lys 125 130 135 140 tgc aag agt gac att aag aag atg agg gag gag ctg gcg gcc aga agc 541 Cys Lys Ser Asp Ile Lys Lys Met Arg Glu Glu Leu Ala Ala Arg Ser 145 150 155 agc agg acc aac tgc ccc tgt aag tac agt ttt ttg gat aac cac aag 589 Ser Arg Thr Asn Cys Pro Cys Lys Tyr Ser Phe Leu Asp Asn His Lys 160 165 170 aag ttg act cct cga cgc gat gtt ccc act tac ccc aag tac ctg ctc 637 Lys Leu Thr Pro Arg Arg Asp Val Pro Thr Tyr Pro Lys Tyr Leu Leu 175 180 185 tct cca gag acc atc gag gcc ctg cgg aag ccg acc ttt gac gtc tgg 685 Ser Pro Glu Thr Ile Glu Ala Leu Arg Lys Pro Thr Phe Asp Val Trp 190 195 200 ctt tgg gag ccc aat gag atg ctg agc tgc ctg gag cac atg tac cac 733 Leu Trp Glu Pro Asn Glu Met Leu Ser Cys Leu Glu His Met Tyr His 205 210 215 220 gac ctc ggg ctg gtc agg gac ttc agc atc aac cct gtc acc ctc agg 781 Asp Leu Gly Leu Val Arg Asp Phe Ser Ile Asn Pro Val Thr Leu Arg 225 230 235 agg tgg ctg ttc tgc gtc cac gac aac tac aga aac aac ccc ttc cac 829 Arg Trp Leu Phe Cys Val His Asp Asn Tyr Arg Asn Asn Pro Phe His 240 245 250 aac ttc cgg cac tgc ttc tgc gtg gcc cag atg atg tac agc atg gtc 877 Asn Phe Arg His Cys Phe Cys Val Ala Gln Met Met Tyr Ser Met Val 255 260 265 tgg ctc tgc agt ctc cag gag aag ttc tca caa acg gat atc ctg atc 925 Trp Leu Cys Ser Leu Gln Glu Lys Phe Ser Gln Thr Asp Ile Leu Ile 270 275 280 cta atg aca gcg gcc atc tgc cac gat ctg gac cat ccc ggc tac aac 973 Leu Met Thr Ala Ala Ile Cys His Asp Leu Asp His Pro Gly Tyr Asn 285 290 295 300 aac acg tac cag atc aat gcc cgc aca gag ctg gcg gtc cgc tac aat 1021 Asn Thr Tyr Gln Ile Asn Ala Arg Thr Glu Leu Ala Val Arg Tyr Asn 305 310 315 gac atc tca ccg ctg gag aac cac cac tgc gcc gtg gcc ttc cag atc 1069 Asp Ile Ser Pro Leu Glu Asn His His Cys Ala Val Ala Phe Gln Ile 320 325 330 ctc gcc gag cct gag tgc aac atc ttc tcc aac atc cca cct gat ggg 1117 Leu Ala Glu Pro Glu Cys Asn Ile Phe Ser Asn Ile Pro Pro Asp Gly 335 340 345 ttc aag cag atc cga cag gga atg atc aca tta atc ttg gcc act gac 1165 Phe Lys Gln Ile Arg Gln Gly Met Ile Thr Leu Ile Leu Ala Thr Asp 350 355 360 atg gca aga cat gca gaa att atg gat tct ttc aaa gag aaa atg gag 1213 Met Ala Arg His Ala Glu Ile Met Asp Ser Phe Lys Glu Lys Met Glu 365 370 375 380 aat ttt gac tac agc aac gag gag cac atg acc ctg ctg aag atg att 1261 Asn Phe Asp Tyr Ser Asn Glu Glu His Met Thr Leu Leu Lys Met Ile 385 390 395 ttg ata aaa tgc tgt gat atc tct aac gag gtc cgt cca atg gaa gtc 1309 Leu Ile Lys Cys Cys Asp Ile Ser Asn Glu Val Arg Pro Met Glu Val 400 405 410 gca gag cct tgg gtg gac tgt tta tta gag gaa tat ttt atg cag agc 1357 Ala Glu Pro Trp Val Asp Cys Leu Leu Glu Glu Tyr Phe Met Gln Ser 415 420 425 gac cgt gag aag tca gaa ggc ctt cct gtg gca ccg ttc atg gac cga 1405 Asp Arg Glu Lys Ser Glu Gly Leu Pro Val Ala Pro Phe Met Asp Arg 430 435 440 gac aaa gtg acc aag gcc aca gcc cag att ggg ttc atc aag ttt gtc 1453 Asp Lys Val Thr Lys Ala Thr Ala Gln Ile Gly Phe Ile Lys Phe Val 445 450 455 460 ctg atc cca atg ttt gaa aca gtg acc aag ctc ttc ccc atg gtt gag 1501 Leu Ile Pro Met Phe Glu Thr Val Thr Lys Leu Phe Pro Met Val Glu 465 470 475 gag atc atg ctg cag cca ctt tgg gaa tcc cga gat cgc tac gag gag 1549 Glu Ile Met Leu Gln Pro Leu Trp Glu Ser Arg Asp Arg Tyr Glu Glu 480 485 490 ctg aag cgg ata gat gac gcc atg aaa gag tta cag aag aag act gac 1597 Leu Lys Arg Ile Asp Asp Ala Met Lys Glu Leu Gln Lys Lys Thr Asp 495 500 505 agc ttg acg tct ggg gcc acc gag aag tcc aga gag aga agc aga gat 1645 Ser Leu Thr Ser Gly Ala Thr Glu Lys Ser Arg Glu Arg Ser Arg Asp 510 515 520 gtg aaa aac agt gaa gga gac tgt gcc tgaggaaagc ggggggcgtg 1692 Val Lys Asn Ser Glu Gly Asp Cys Ala 525 530 gctgcagttc tggacgggct ggccgagctg cgcgggatcc ttgtgcaggg aagagctgcc 1752 ctgggcacct ggcaccacaa gaccatgttt tctaagaacc attttgttca ctgataaaaa 1812 aaaaaaaaaa ggaattcatg atgctgtaca gaattttatt tttaaactgt cttttaaata 1872 atatattctt atacg 1887 19 533 PRT Homo sapiens 19 Met Gly Ser Gly Ser Ser Ser Tyr Arg Pro Lys Ala Ile Tyr Leu Asp 1 5 10 15 Ile Asp Gly Arg Ile Gln Lys Val Ile Phe Ser Lys Tyr Cys Asn Ser 20 25 30 Ser Asp Ile Met Asp Leu Phe Cys Ile Ala Thr Gly Leu Pro Arg Asn 35 40 45 Thr Thr Ile Ser Leu Leu Thr Thr Asp Asp Ala Met Val Ser Ile Asp 50 55 60 Pro Thr Met Pro Ala Asn Ser Glu Arg Thr Pro Tyr Lys Val Arg Pro 65 70 75 80 Val Ala Ile Lys Gln Leu Ser Glu Arg Glu Glu Leu Ile Gln Ser Val 85 90 95 Leu Ala Gln Val Ala Glu Gln Phe Ser Arg Ala Phe Lys Ile Asn Glu 100 105 110 Leu Lys Ala Glu Val Ala Asn His Leu Ala Val Leu Glu Lys Arg Val 115 120 125 Glu Leu Glu Gly Leu Lys Val Val Glu Ile Glu Lys Cys Lys Ser Asp 130 135 140 Ile Lys Lys Met Arg Glu Glu Leu Ala Ala Arg Ser Ser Arg Thr Asn 145 150 155 160 Cys Pro Cys Lys Tyr Ser Phe Leu Asp Asn His Lys Lys Leu Thr Pro 165 170 175 Arg Arg Asp Val Pro Thr Tyr Pro Lys Tyr Leu Leu Ser Pro Glu Thr 180 185 190 Ile Glu Ala Leu Arg Lys Pro Thr Phe Asp Val Trp Leu Trp Glu Pro 195 200 205 Asn Glu Met Leu Ser Cys Leu Glu His Met Tyr His Asp Leu Gly Leu 210 215 220 Val Arg Asp Phe Ser Ile Asn Pro Val Thr Leu Arg Arg Trp Leu Phe 225 230 235 240 Cys Val His Asp Asn Tyr Arg Asn Asn Pro Phe His Asn Phe Arg His 245 250 255 Cys Phe Cys Val Ala Gln Met Met Tyr Ser Met Val Trp Leu Cys Ser 260 265 270 Leu Gln Glu Lys Phe Ser Gln Thr Asp Ile Leu Ile Leu Met Thr Ala 275 280 285 Ala Ile Cys His Asp Leu Asp His Pro Gly Tyr Asn Asn Thr Tyr Gln 290 295 300 Ile Asn Ala Arg Thr Glu Leu Ala Val Arg Tyr Asn Asp Ile Ser Pro 305 310 315 320 Leu Glu Asn His His Cys Ala Val Ala Phe Gln Ile Leu Ala Glu Pro 325 330 335 Glu Cys Asn Ile Phe Ser Asn Ile Pro Pro Asp Gly Phe Lys Gln Ile 340 345 350 Arg Gln Gly Met Ile Thr Leu Ile Leu Ala Thr Asp Met Ala Arg His 355 360 365 Ala Glu Ile Met Asp Ser Phe Lys Glu Lys Met Glu Asn Phe Asp Tyr 370 375 380 Ser Asn Glu Glu His Met Thr Leu Leu Lys Met Ile Leu Ile Lys Cys 385 390 395 400 Cys Asp Ile Ser Asn Glu Val Arg Pro Met Glu Val Ala Glu Pro Trp 405 410 415 Val Asp Cys Leu Leu Glu Glu Tyr Phe Met Gln Ser Asp Arg Glu Lys 420 425 430 Ser Glu Gly Leu Pro Val Ala Pro Phe Met Asp Arg Asp Lys Val Thr 435 440 445 Lys Ala Thr Ala Gln Ile Gly Phe Ile Lys Phe Val Leu Ile Pro Met 450 455 460 Phe Glu Thr Val Thr Lys Leu Phe Pro Met Val Glu Glu Ile Met Leu 465 470 475 480 Gln Pro Leu Trp Glu Ser Arg Asp Arg Tyr Glu Glu Leu Lys Arg Ile 485 490 495 Asp Asp Ala Met Lys Glu Leu Gln Lys Lys Thr Asp Ser Leu Thr Ser 500 505 510 Gly Ala Thr Glu Lys Ser Arg Glu Arg Ser Arg Asp Val Lys Asn Ser 515 520 525 Glu Gly Asp Cys Ala 530 20 1967 DNA Homo sapiens CDS (2)..(1741) 20 c tac ctg gac atc gat gga cgc att cag aag gta atc ttc agc aag tac 49 Tyr Leu Asp Ile Asp Gly Arg Ile Gln Lys Val Ile Phe Ser Lys Tyr 1 5 10 15 tgc aac tcc agc gac atc atg gac ctg ttc tgc atc gcc acc ggc ctg 97 Cys Asn Ser Ser Asp Ile Met Asp Leu Phe Cys Ile Ala Thr Gly Leu 20 25 30 cct cgg aac acg acc atc tcc ctg ctg acc acc gac gac gcc atg gtc 145 Pro Arg Asn Thr Thr Ile Ser Leu Leu Thr Thr Asp Asp Ala Met Val 35 40 45 tcc atc gac ccc acc atg ccc gcg aat tca gaa cgc act ccg tac aaa 193 Ser Ile Asp Pro Thr Met Pro Ala Asn Ser Glu Arg Thr Pro Tyr Lys 50 55 60 gtg aga cct gtg gcc atc aag caa ctc tcc gct gat gtc gag gac aag 241 Val Arg Pro Val Ala Ile Lys Gln Leu Ser Ala Asp Val Glu Asp Lys 65 70 75 80 aga acc aca agc cgt ggc cag tct gct gag aga cca ctg agg gac aga 289 Arg Thr Thr Ser Arg Gly Gln Ser Ala Glu Arg Pro Leu Arg Asp Arg 85 90 95 cgg gtt gtg ggc ctg gag cag ccc cgg agg gaa gga gca ttt gaa agt 337 Arg Val Val Gly Leu Glu Gln Pro Arg Arg Glu Gly Ala Phe Glu Ser 100 105 110 gga cag gta gag ccc agg ccc aga gag ccc cag ggc tgc tac cag gaa 385 Gly Gln Val Glu Pro Arg Pro Arg Glu Pro Gln Gly Cys Tyr Gln Glu 115 120 125 ggc cag cgc atc cct cca gag aga gaa gaa tta atc cag agc gtg ctg 433 Gly Gln Arg Ile Pro Pro Glu Arg Glu Glu Leu Ile Gln Ser Val Leu 130 135 140 gcg cag gtt gca gag cag ttc tca aga gca ttc aaa atc aat gaa ctg 481 Ala Gln Val Ala Glu Gln Phe Ser Arg Ala Phe Lys Ile Asn Glu Leu 145 150 155 160 aaa gct gaa gtt gca aat cac ttg gct gtc cta gag aaa cgc gtg gaa 529 Lys Ala Glu Val Ala Asn His Leu Ala Val Leu Glu Lys Arg Val Glu 165 170 175 ttg gaa gga cta aaa gtg gtg gag att gag aaa tgc aag agt gac att 577 Leu Glu Gly Leu Lys Val Val Glu Ile Glu Lys Cys Lys Ser Asp Ile 180 185 190 aag aag atg agg gag gag ctg gcg gcc aga agc agc agg acc aac tgc 625 Lys Lys Met Arg Glu Glu Leu Ala Ala Arg Ser Ser Arg Thr Asn Cys 195 200 205 ccc tgt aag tac agt ttt ttg gat aac cac aag aag ttg act cct cga 673 Pro Cys Lys Tyr Ser Phe Leu Asp Asn His Lys Lys Leu Thr Pro Arg 210 215 220 cgc gat gtt ccc act tac ccc aag tac ctg ctc tct cca gag acc atc 721 Arg Asp Val Pro Thr Tyr Pro Lys Tyr Leu Leu Ser Pro Glu Thr Ile 225 230 235 240 gag gcc ctg cgg aag ccg acc ttt gac gtc tgg ctt tgg gag ccc aat 769 Glu Ala Leu Arg Lys Pro Thr Phe Asp Val Trp Leu Trp Glu Pro Asn 245 250 255 gag atg ctg agc tgc ctg gag cac atg tac cac gac ctc ggg ctg gtc 817 Glu Met Leu Ser Cys Leu Glu His Met Tyr His Asp Leu Gly Leu Val 260 265 270 agg gac ttc agc atc aac cct gtc acc ctc agg agg tgg ctg ttc tgc 865 Arg Asp Phe Ser Ile Asn Pro Val Thr Leu Arg Arg Trp Leu Phe Cys 275 280 285 gtc cac gac aac tac aga aac aac ccc ttc cac aac ttc cgg cac tgc 913 Val His Asp Asn Tyr Arg Asn Asn Pro Phe His Asn Phe Arg His Cys 290 295 300 ttc tgc gtg gcc cag atg atg tac agc atg gtc tgg ctc tgc agt ctc 961 Phe Cys Val Ala Gln Met Met Tyr Ser Met Val Trp Leu Cys Ser Leu 305 310 315 320 cag gag aag ttc tca caa acg gat atc ctg atc cta atg aca gcg gcc 1009 Gln Glu Lys Phe Ser Gln Thr Asp Ile Leu Ile Leu Met Thr Ala Ala 325 330 335 atc tgc cac gat ctg gac cat ccc ggc tac aac aac acg tac cag atc 1057 Ile Cys His Asp Leu Asp His Pro Gly Tyr Asn Asn Thr Tyr Gln Ile 340 345 350 aat gcc cgc aca gag ctg gcg gtc cgc tac aat gac atc tca ccg ctg 1105 Asn Ala Arg Thr Glu Leu Ala Val Arg Tyr Asn Asp Ile Ser Pro Leu 355 360 365 gag aac cac cac tgc gcc gtg gcc ttc cag atc ctc gcc gag cct gag 1153 Glu Asn His His Cys Ala Val Ala Phe Gln Ile Leu Ala Glu Pro Glu 370 375 380 tgc aac atc ttc tcc aac atc cca cct gat ggg ttc aag cag atc cga 1201 Cys Asn Ile Phe Ser Asn Ile Pro Pro Asp Gly Phe Lys Gln Ile Arg 385 390 395 400 cag gga atg atc aca tta atc ttg gcc act gac atg gca aga cat gca 1249 Gln Gly Met Ile Thr Leu Ile Leu Ala Thr Asp Met Ala Arg His Ala 405 410 415 gaa att atg gat tct ttc aaa gag aaa atg gag aat ttt gac tac agc 1297 Glu Ile Met Asp Ser Phe Lys Glu Lys Met Glu Asn Phe Asp Tyr Ser 420 425 430 aac gag gag cac atg acc ctg ctg aag atg att ttg ata aaa tgc tgt 1345 Asn Glu Glu His Met Thr Leu Leu Lys Met Ile Leu Ile Lys Cys Cys 435 440 445 gat atc tct aac gag gtc cgt cca atg gaa gtc gca gag cct tgg gtg 1393 Asp Ile Ser Asn Glu Val Arg Pro Met Glu Val Ala Glu Pro Trp Val 450 455 460 gac tgt tta tta gag gaa tat ttt atg cag agc gac cgt gag aag tca 1441 Asp Cys Leu Leu Glu Glu Tyr Phe Met Gln Ser Asp Arg Glu Lys Ser 465 470 475 480 gaa ggc ctt cct gtg gca ccg ttc atg gac cga gac aaa gtg acc aag 1489 Glu Gly Leu Pro Val Ala Pro Phe Met Asp Arg Asp Lys Val Thr Lys 485 490 495 gcc aca gcc cag att ggg ttc atc aag ttt gtc ctg atc cca atg ttt 1537 Ala Thr Ala Gln Ile Gly Phe Ile Lys Phe Val Leu Ile Pro Met Phe 500 505 510 gaa aca gtg acc aag ctc ttc ccc atg gtt gag gag atc atg ctg cag 1585 Glu Thr Val Thr Lys Leu Phe Pro Met Val Glu Glu Ile Met Leu Gln 515 520 525 cca ctt tgg gaa tcc cga gat cgc tac gag gag ctg aag cgg ata gat 1633 Pro Leu Trp Glu Ser Arg Asp Arg Tyr Glu Glu Leu Lys Arg Ile Asp 530 535 540 gac gcc atg aaa gag tta cag aag aag act gac agc ttg acg tct ggg 1681 Asp Ala Met Lys Glu Leu Gln Lys Lys Thr Asp Ser Leu Thr Ser Gly 545 550 555 560 gcc acc gag aag tcc aga gag aga agc aga gat gtg aaa aac agt gaa 1729 Ala Thr Glu Lys Ser Arg Glu Arg Ser Arg Asp Val Lys Asn Ser Glu 565 570 575 gga gac tgt gcc tgaggaaagc ggggggcgtg gctgcagttc tggacgggct 1781 Gly Asp Cys Ala 580 ggccgagctg cgcgggatcc ttgtgcaggg aagagctgcc ctgggcacct ggcaccacaa 1841 gaccatgttt tctaagaacc attttgttca ctgatacaaa aaaaaaaaaa ggaattcatg 1901 atgctgtaca gaattttatt tttaaactgt cttttaaata atatattctt atacggaaaa 1961 aaaaaa 1967 21 580 PRT Homo sapiens 21 Tyr Leu Asp Ile Asp Gly Arg Ile Gln Lys Val Ile Phe Ser Lys Tyr 1 5 10 15 Cys Asn Ser Ser Asp Ile Met Asp Leu Phe Cys Ile Ala Thr Gly Leu 20 25 30 Pro Arg Asn Thr Thr Ile Ser Leu Leu Thr Thr Asp Asp Ala Met Val 35 40 45 Ser Ile Asp Pro Thr Met Pro Ala Asn Ser Glu Arg Thr Pro Tyr Lys 50 55 60 Val Arg Pro Val Ala Ile Lys Gln Leu Ser Ala Asp Val Glu Asp Lys 65 70 75 80 Arg Thr Thr Ser Arg Gly Gln Ser Ala Glu Arg Pro Leu Arg Asp Arg 85 90 95 Arg Val Val Gly Leu Glu Gln Pro Arg Arg Glu Gly Ala Phe Glu Ser 100 105 110 Gly Gln Val Glu Pro Arg Pro Arg Glu Pro Gln Gly Cys Tyr Gln Glu 115 120 125 Gly Gln Arg Ile Pro Pro Glu Arg Glu Glu Leu Ile Gln Ser Val Leu 130 135 140 Ala Gln Val Ala Glu Gln Phe Ser Arg Ala Phe Lys Ile Asn Glu Leu 145 150 155 160 Lys Ala Glu Val Ala Asn His Leu Ala Val Leu Glu Lys Arg Val Glu 165 170 175 Leu Glu Gly Leu Lys Val Val Glu Ile Glu Lys Cys Lys Ser Asp Ile 180 185 190 Lys Lys Met Arg Glu Glu Leu Ala Ala Arg Ser Ser Arg Thr Asn Cys 195 200 205 Pro Cys Lys Tyr Ser Phe Leu Asp Asn His Lys Lys Leu Thr Pro Arg 210 215 220 Arg Asp Val Pro Thr Tyr Pro Lys Tyr Leu Leu Ser Pro Glu Thr Ile 225 230 235 240 Glu Ala Leu Arg Lys Pro Thr Phe Asp Val Trp Leu Trp Glu Pro Asn 245 250 255 Glu Met Leu Ser Cys Leu Glu His Met Tyr His Asp Leu Gly Leu Val 260 265 270 Arg Asp Phe Ser Ile Asn Pro Val Thr Leu Arg Arg Trp Leu Phe Cys 275 280 285 Val His Asp Asn Tyr Arg Asn Asn Pro Phe His Asn Phe Arg His Cys 290 295 300 Phe Cys Val Ala Gln Met Met Tyr Ser Met Val Trp Leu Cys Ser Leu 305 310 315 320 Gln Glu Lys Phe Ser Gln Thr Asp Ile Leu Ile Leu Met Thr Ala Ala 325 330 335 Ile Cys His Asp Leu Asp His Pro Gly Tyr Asn Asn Thr Tyr Gln Ile 340 345 350 Asn Ala Arg Thr Glu Leu Ala Val Arg Tyr Asn Asp Ile Ser Pro Leu 355 360 365 Glu Asn His His Cys Ala Val Ala Phe Gln Ile Leu Ala Glu Pro Glu 370 375 380 Cys Asn Ile Phe Ser Asn Ile Pro Pro Asp Gly Phe Lys Gln Ile Arg 385 390 395 400 Gln Gly Met Ile Thr Leu Ile Leu Ala Thr Asp Met Ala Arg His Ala 405 410 415 Glu Ile Met Asp Ser Phe Lys Glu Lys Met Glu Asn Phe Asp Tyr Ser 420 425 430 Asn Glu Glu His Met Thr Leu Leu Lys Met Ile Leu Ile Lys Cys Cys 435 440 445 Asp Ile Ser Asn Glu Val Arg Pro Met Glu Val Ala Glu Pro Trp Val 450 455 460 Asp Cys Leu Leu Glu Glu Tyr Phe Met Gln Ser Asp Arg Glu Lys Ser 465 470 475 480 Glu Gly Leu Pro Val Ala Pro Phe Met Asp Arg Asp Lys Val Thr Lys 485 490 495 Ala Thr Ala Gln Ile Gly Phe Ile Lys Phe Val Leu Ile Pro Met Phe 500 505 510 Glu Thr Val Thr Lys Leu Phe Pro Met Val Glu Glu Ile Met Leu Gln 515 520 525 Pro Leu Trp Glu Ser Arg Asp Arg Tyr Glu Glu Leu Lys Arg Ile Asp 530 535 540 Asp Ala Met Lys Glu Leu Gln Lys Lys Thr Asp Ser Leu Thr Ser Gly 545 550 555 560 Ala Thr Glu Lys Ser Arg Glu Arg Ser Arg Asp Val Lys Asn Ser Glu 565 570 575 Gly Asp Cys Ala 580 22 1457 DNA Homo sapiens CDS (164)..(1453) 22 ggctcccggg cgtcccgggc ccggtggcgg cgcggctgtg gttggctgag cgccgcgggc 60 cgccccccgc ccgccccctc ccctgctccc ctcccccgcc tcccgcggcg gctggcgtcg 120 ggaaagtaca gtaaaaagtc cgagtgcagc cgccgggcgc agg atg gga tcc ggc 175 Met Gly Ser Gly 1 tcc tcc agc tac cgg ccc aag gcc atc tac ctg gac atc gat gga cgc 223 Ser Ser Ser Tyr Arg Pro Lys Ala Ile Tyr Leu Asp Ile Asp Gly Arg 5 10 15 20 att cag aag gta atc ttc agc aag tac tgc aac tcc agc gac atc atg 271 Ile Gln Lys Val Ile Phe Ser Lys Tyr Cys Asn Ser Ser Asp Ile Met 25 30 35 gac ctg ttc tgc atc gcc acc ggc ctg cct cgg aac acg acc atc tcc 319 Asp Leu Phe Cys Ile Ala Thr Gly Leu Pro Arg Asn Thr Thr Ile Ser 40 45 50 ctg ctg acc acc gac gac gcc atg gtc tcc atc gac ccc acc atg ccc 367 Leu Leu Thr Thr Asp Asp Ala Met Val Ser Ile Asp Pro Thr Met Pro 55 60 65 gcg aat tca gaa cgc act ccg tac aaa gtg aga cct gtg gcc atc aag 415 Ala Asn Ser Glu Arg Thr Pro Tyr Lys Val Arg Pro Val Ala Ile Lys 70 75 80 caa ctc tcc gag aga gaa gaa tta atc cag agc gtg ctg gcg cag gtt 463 Gln Leu Ser Glu Arg Glu Glu Leu Ile Gln Ser Val Leu Ala Gln Val 85 90 95 100 gca gag cag ttc tca aga gca ttc aaa atc aat gaa ctg aaa gct gaa 511 Ala Glu Gln Phe Ser Arg Ala Phe Lys Ile Asn Glu Leu Lys Ala Glu 105 110 115 gtt gca aat cac ttg gct gtc cta gag aaa cgc gtg gaa ttg gaa gga 559 Val Ala Asn His Leu Ala Val Leu Glu Lys Arg Val Glu Leu Glu Gly 120 125 130 cta aaa gtg gtg gag att gag aaa tgc aag agt gac att aag aag atg 607 Leu Lys Val Val Glu Ile Glu Lys Cys Lys Ser Asp Ile Lys Lys Met 135 140 145 agg gag gag ctg gcg gcc aga agc agc agg acc aac tgc ccc tgt aag 655 Arg Glu Glu Leu Ala Ala Arg Ser Ser Arg Thr Asn Cys Pro Cys Lys 150 155 160 tac agt ttt ttg gat aac cac aag aag ttg act cct cga cgc gat gtt 703 Tyr Ser Phe Leu Asp Asn His Lys Lys Leu Thr Pro Arg Arg Asp Val 165 170 175 180 ccc act tac ccc aag tac ctg ctc tct cca gag acc atc gag gcc ctg 751 Pro Thr Tyr Pro Lys Tyr Leu Leu Ser Pro Glu Thr Ile Glu Ala Leu 185 190 195 cgg aag ccg acc ttt gac gtc tgg ctt tgg gag ccc aat gag atg ctg 799 Arg Lys Pro Thr Phe Asp Val Trp Leu Trp Glu Pro Asn Glu Met Leu 200 205 210 agc tgc ctg gag cac atg tac cac gac ctc ggg ctg gtc agg gac ttc 847 Ser Cys Leu Glu His Met Tyr His Asp Leu Gly Leu Val Arg Asp Phe 215 220 225 agc atc aac cct gtc acc ctc agg agg tgg ctg ttc tgc gtc cac gac 895 Ser Ile Asn Pro Val Thr Leu Arg Arg Trp Leu Phe Cys Val His Asp 230 235 240 aac tac aga aac aac ccc ttc cac aac ttc cgg cac tgc ttc tgc gtg 943 Asn Tyr Arg Asn Asn Pro Phe His Asn Phe Arg His Cys Phe Cys Val 245 250 255 260 gcc cag atg atg tac agc atg gtc tgg ctc tgc agt ctc cag gag aag 991 Ala Gln Met Met Tyr Ser Met Val Trp Leu Cys Ser Leu Gln Glu Lys 265 270 275 ttc tca caa acg gat atc ctg atc cta atg aca gcg gcc atc tgc cac 1039 Phe Ser Gln Thr Asp Ile Leu Ile Leu Met Thr Ala Ala Ile Cys His 280 285 290 gat ctg gac cat ccc ggc tac aac aac acg tac cag atc aat gcc cgc 1087 Asp Leu Asp His Pro Gly Tyr Asn Asn Thr Tyr Gln Ile Asn Ala Arg 295 300 305 aca gag ctg gcg gtc cgc tac aat gac atc tca ccg ctg gag aac cac 1135 Thr Glu Leu Ala Val Arg Tyr Asn Asp Ile Ser Pro Leu Glu Asn His 310 315 320 cac tgc gcc gtg gcc ttc cag atc ctc gcc gag cct gag tgc aac atc 1183 His Cys Ala Val Ala Phe Gln Ile Leu Ala Glu Pro Glu Cys Asn Ile 325 330 335 340 ttc tcc aac atc cca cct gat ggg ttc aag cag atc cga cag gga atg 1231 Phe Ser Asn Ile Pro Pro Asp Gly Phe Lys Gln Ile Arg Gln Gly Met 345 350 355 atc aca tta atc ttg gcc act gac atg gca aga cat gca gaa att atg 1279 Ile Thr Leu Ile Leu Ala Thr Asp Met Ala Arg His Ala Glu Ile Met 360 365 370 gat tct ttc aaa gag aaa atg gag aat ttt gac tac agc aac gag gag 1327 Asp Ser Phe Lys Glu Lys Met Glu Asn Phe Asp Tyr Ser Asn Glu Glu 375 380 385 cac atg acc ctg ctg aag atg att ttg ata aaa tgc tgt gat atc tct 1375 His Met Thr Leu Leu Lys Met Ile Leu Ile Lys Cys Cys Asp Ile Ser 390 395 400 aac gag gtc cgt cca atg gaa gtc gca gag cct tgg gtg gac tgt tta 1423 Asn Glu Val Arg Pro Met Glu Val Ala Glu Pro Trp Val Asp Cys Leu 405 410 415 420 tta gag gaa tat ttt atg cag agc gac cgt gaga 1457 Leu Glu Glu Tyr Phe Met Gln Ser Asp Arg 425 430 23 430 PRT Homo sapiens 23 Met Gly Ser Gly Ser Ser Ser Tyr Arg Pro Lys Ala Ile Tyr Leu Asp 1 5 10 15 Ile Asp Gly Arg Ile Gln Lys Val Ile Phe Ser Lys Tyr Cys Asn Ser 20 25 30 Ser Asp Ile Met Asp Leu Phe Cys Ile Ala Thr Gly Leu Pro Arg Asn 35 40 45 Thr Thr Ile Ser Leu Leu Thr Thr Asp Asp Ala Met Val Ser Ile Asp 50 55 60 Pro Thr Met Pro Ala Asn Ser Glu Arg Thr Pro Tyr Lys Val Arg Pro 65 70 75 80 Val Ala Ile Lys Gln Leu Ser Glu Arg Glu Glu Leu Ile Gln Ser Val 85 90 95 Leu Ala Gln Val Ala Glu Gln Phe Ser Arg Ala Phe Lys Ile Asn Glu 100 105 110 Leu Lys Ala Glu Val Ala Asn His Leu Ala Val Leu Glu Lys Arg Val 115 120 125 Glu Leu Glu Gly Leu Lys Val Val Glu Ile Glu Lys Cys Lys Ser Asp 130 135 140 Ile Lys Lys Met Arg Glu Glu Leu Ala Ala Arg Ser Ser Arg Thr Asn 145 150 155 160 Cys Pro Cys Lys Tyr Ser Phe Leu Asp Asn His Lys Lys Leu Thr Pro 165 170 175 Arg Arg Asp Val Pro Thr Tyr Pro Lys Tyr Leu Leu Ser Pro Glu Thr 180 185 190 Ile Glu Ala Leu Arg Lys Pro Thr Phe Asp Val Trp Leu Trp Glu Pro 195 200 205 Asn Glu Met Leu Ser Cys Leu Glu His Met Tyr His Asp Leu Gly Leu 210 215 220 Val Arg Asp Phe Ser Ile Asn Pro Val Thr Leu Arg Arg Trp Leu Phe 225 230 235 240 Cys Val His Asp Asn Tyr Arg Asn Asn Pro Phe His Asn Phe Arg His 245 250 255 Cys Phe Cys Val Ala Gln Met Met Tyr Ser Met Val Trp Leu Cys Ser 260 265 270 Leu Gln Glu Lys Phe Ser Gln Thr Asp Ile Leu Ile Leu Met Thr Ala 275 280 285 Ala Ile Cys His Asp Leu Asp His Pro Gly Tyr Asn Asn Thr Tyr Gln 290 295 300 Ile Asn Ala Arg Thr Glu Leu Ala Val Arg Tyr Asn Asp Ile Ser Pro 305 310 315 320 Leu Glu Asn His His Cys Ala Val Ala Phe Gln Ile Leu Ala Glu Pro 325 330 335 Glu Cys Asn Ile Phe Ser Asn Ile Pro Pro Asp Gly Phe Lys Gln Ile 340 345 350 Arg Gln Gly Met Ile Thr Leu Ile Leu Ala Thr Asp Met Ala Arg His 355 360 365 Ala Glu Ile Met Asp Ser Phe Lys Glu Lys Met Glu Asn Phe Asp Tyr 370 375 380 Ser Asn Glu Glu His Met Thr Leu Leu Lys Met Ile Leu Ile Lys Cys 385 390 395 400 Cys Asp Ile Ser Asn Glu Val Arg Pro Met Glu Val Ala Glu Pro Trp 405 410 415 Val Asp Cys Leu Leu Glu Glu Tyr Phe Met Gln Ser Asp Arg 420 425 430 24 8 PRT Artificial Sequence Description of Artificial Sequence FLAG epit ope 24 Asp Thr Lys Asp Asp Asp Asp Lys 1 5 25 54 DNA Artificial Sequence Description of Artificial Sequence primer 25 tagaccatgg actacaagga cgacgatgac aagatggacg cattcagaag cact 54 26 18 DNA Artificial Sequence Description of Artificial Sequence primer 26 cgaggagtca acttcttg 18 

What is claimed is:
 1. A purified and isolated PDE10 polypeptide.
 2. The polypeptide according to claim 1 comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 18, SEQ ID NO: 20 and SEQ ID NO:
 22. 3. A polynucleotide encoding the polypeptide according to claim 1 or
 2. 4. The polynucleotide according to claim 3 comprising the sequence set forth in SEQ ID NO:
 1. 5. A polynucleotide encoding a human PDE10 polypeptide selected from the group consisting of: a) the polynucleotide according to claim 4; b) a DNA which hybridizes under moderately stringent conditions to the non-coding strand of the polynucleotide of (a); and c) a DNA which would hybridize to the non-coding strand of the polynucleotide of (a) but for the redundancy of the genetic code.
 6. The polynucleotide of claim 5 comprising the polynucleotide sequence set out in SEQ ID NO:
 18. 7. The polynucleotide of claim 5 comprising the polynucleotide sequence set out in SEQ ID NO:
 20. 8. The polynucleotide of claim 5 comprising the polynucleotide sequence set out in SEQ ID NO:
 22. 9. The polynucleotide of claim 5 which is a DNA molecule.
 10. The DNA of claim 9 which is a cDNA molecule.
 11. The DNA of claim 9 which is a wholly or partially chemically synthesized DNA molecule.
 12. A polynucleotide comprising the sequence set out in SEQ ID NO: 1 or a fragment thereof.
 13. A polynucleotide comprising the sequence set out in SEQ ID NO: 18 or a fragment thereof.
 14. A polynucleotide comprising the sequence set out in SEQ ID NO: 20 or a fragment thereof.
 15. A polynucleotide comprising the sequence set out in SEQ ID NO: 22 or a fragment thereof.
 16. An anti-sense polynucleotide which specifically hybridizes with the complement of the polynucleotide of claim
 5. 17. A expression construct comprising the polynucleotide according to claim
 5. 18. A host cell transformed or transfected with the expression construct according to claim
 17. 19. A method for producing a PDE10 polypeptide comprising the steps of: a) growing the host cell according to claim 18 under conditions appropriate for expression of the PDE10 polypeptide and b) isolating the PDE10 polypeptide from the host cell or the medium of its growth.
 20. An antibody specifically immunoreactive with the polypeptide according to claim 1 or
 2. 21. The antibody according to claim 20 which is a monoclonal antibody.
 22. A hybridoma which produces the antibody according to claim
 21. 23. An anti-idiotype antibody specifically immunoreactive with the antibody according to claim
 21. 24. A method to identify a specific binding partner compound of the PDE10 polypeptide according to claim 1 or 2 comprising the steps of: a) contacting the PDE10 polypeptide with a compound under conditions which permit binding between the compound and the PDE10 polypeptide; b) detecting binding of the compound to the PDE10 polypeptide; and c) identifying the compound as a specific binding partner of the PDE10 polypeptide.
 25. The method according to claim 24 wherein the specific binding partner modulates activity of the PDE10 polypeptide.
 26. The method according to claim 25 wherein the compound inhibits activity of the PDE10 polypeptide.
 27. The method according to claim 25 wherein the compound enhances activity of the PDE10 polypeptide.
 28. A method to identify a specific binding partner compound of the PDE10 polynucleotide according to claim 5 comprising the steps of: a) contacting the PDE10 polynucleotide with a compound under conditions which permit binding between the compound and the PDE10 polynucleotide; b) detecting binding of the compound to the PDE10 polynucleotide; and c) identifying the compound as a specific binding partner of the PDE10 polynucleotide.
 29. The method according to claim 28 wherein the specific binding partner modulates expression of a PDE10 polypeptide encoded by the PDE10 polynucleotide.
 30. The method according to claim 29 wherein the compound inhibits expression of the PDE10 polypeptide.
 31. The method according to claim 29 wherein the compound enhances expression of the PDE10 polypeptide.
 32. A compound identified by the method according to claim 24 or
 28. 33. A composition comprising the compound according to claim 32 and a pharmaceutically acceptable carrier. 